

(A joint stock limited liability company incorporated in the People's Republic of China)

Stock cod



Contents

	P
CORPORATE INFORMATION	2
FINANCIAL HIGHLIGHTS	4
MANAGEMENT DISCUSSION AND ANALYSIS	5
CORPORATE GOVERNANCE AND OTHER INFORMATION	27
CONSOLIDATED BALANCE SHEET	37
PARENT COMPANY BALANCE SHEET	41
CONSOLIDATED INCOME STATEMENT	45
PARENT COMPANY INCOME STATEMENT	47
CONSOLIDATED CASH FLOW STATEMENT	49
PARENT COMPANY CASH FLOW STATEMENT	52
CONSOLIDATED STATEMENT OF CHANGE IN SHAREHOLDER EQUITY	54
PARENT COMPANY STATEMENT OF CHANGE IN SHAREHOLDER EQUITY	56
NOTES TO THE FINANCIAL STATEMENTS	58
DEFINITIONS	136

C, aelf, ai

B, D

E ecti e D,ect,xi

M. G AN (Cn)
M. ANG L
M. ANG J (- , - J 9, 2023)

N. -e ecti e D,ect,xi

M. QIN H -
M. LI Cn n -

I. de e. de N. -e ecti e D,ect,xi

M. HONG
M. JIN L (- , - J 9, 2023)
M. CHAN, K H - (- , - J 9, 2023)
M. HAO - (- , - M n10, 2023)
M. LI N (- , - J 9, 2023)

A, C-

M. HONG (Cn)
M. LI Cn n -
M. JIN L (- , - J 9, 2023)
M. LI N (- , - J 9, 2023)

N- C-

M. CHAN, K H - (Cn)
(- , - J 9, 2023)
M. G AN
M. JIN L (- , - J 9, 2023)
M. LI N (Cn) (- , - J 9, 2023)
M. HAO - (- , - M n10, 2023)

R C-

M. JIN L (Cn) (- , - J 9, 2023)
M. HONG
M. CHAN, K H - (- , - J 9, 2023)
M. HAO - (Cn) (- , - M n10, 2023)
M. LI N (- , - J 9, 2023)

M, R, C-

M. G AN (Cn)
M. HONG
M. QIN H -

M, / - C-

M. N (Cn)
M. -
M. HANG, (- , - J 9, 2023)
M. IE
M. QIAN Cn

J- C- K-

M. ANG J
M. ONG Cn

A n, R /

M. G AN
M. ONG Cn

A, -

BDO Cn, L P C, P. A - LLP

L A / - H- K- L

C -, Cn

R, O, O n PRC

R, -
H - R, - D
n, n

PRC

C, aelf, ai.

P H_ P _ B
K_

40/F, D n F C
248 Q ' R_ , E
n
H_ K_

H_ R

C_ n H_ K_ I / _ L ,
1712-1716, 17 nF__
H_ C
183 Q ' R_ , E
n
H_ K_

C_

2120

C_ ,

n .

I / _ R _

n : (86) 577 8877 1689
F : (86) 577 8878 9117
E : @ n .

Financial Highlights

Profit and Loss

	For the period ended June 30, 2023	For the period ended June 30, 2022
	(RMB'000)	(RMB'000)
	(U. audited)	(U. audited)
Revenue	777,925	738,305
Cost of services rendered	60,207	63,331
Medical materials	11,478	19,110
Administrative expenses	48,729	44,221
Depreciation and amortization	43,750	38,788
Provisions	4,979	5,433
Net income	113,591	55,974

	As at June 30, 2023	As at June 30, 2022
	(RMB'000)	(RMB'000)
	(U. audited)	(U. audited)
Assets		
Current assets	2,744,233	2,637,787
Non-current assets	1,361,683	1,311,885
Total assets	1,382,550	1,325,903
Equity	1,242,978	1,201,585
Liabilities	139,572	124,318

B LINE, PRE IE AND O LOOK

I n n - 2023, C n , - - - n , - / - - n , n n , - n
 - - - H n C n , n / / - - - , n n n - - , , n
 - - - , n n - , / n , , R - n
 - - - , n G - / , n , - , - n
 n - - / n , - - n n , , / -
 n , / - - - , / n - - :

I n n - 2023, n G - ' - , n n / / - .D n R -
 P - , n G - - - - / - RMB777.9 - , - 5.4% - n
 n - n - .A - n , n / - - - , n - RMB728.7
 - , - 6.7% - , n n - n - . n - n
 G - ' n n n K H , C K H K
 H - , / / - . n / - Q K H - ^ K H -
 , / - n - - - .I , n / -
 ^ - K H - - , n n - n - . n
 ^ - P ^ H - , C n n K P n - H - , H n C H - , Q n ^
 H - n - n - , / - n , n G - - -
 - - / n - - n - - - . n - n -
 n / , - - n A n - n , / / -
 - - / - , n n ^ H - , H K H - , H ^ H -
 G H ^ H - - , n - - / .I , n - - B
 ^ H - n / - - - - .D n
 R - P - , n G - , 51% L , K H - , n n n n - ,
 - ^ - n n - , / - ^ - / -

I n n - 2023, n G - - - - - n - - - - - n n
- , - n n n - - - - - n G H- - - - - n C H-
- . P Cn ^ H- ^ ^ H- , , A 2021 ,
J 2022, / , - , ^ ^ - n - n / - - n - n
- , n n - / - - C ^ N C , n O n ^
E, H- n - , n - - - - -

Management Discussion and Analysis

As of June 30, 2023, the company's total assets were 10,578 million yuan (December 31, 2022: 9,688 million yuan), an increase of 9.1% compared to the end of the last year.

In 2023, the company's total revenue was 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's operating income was 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's net profit was 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's cash and cash equivalents were 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's capital reserves were 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's total liabilities were 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's equity was 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's total shareholders' equity was 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's total non-controlling interests were 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's total comprehensive income was 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's total comprehensive income attributable to shareholders was 10,578 million yuan, an increase of 9.1% compared to the end of the last year. The company's total comprehensive income attributable to non-controlling interests was 10,578 million yuan, an increase of 9.1% compared to the end of the last year.

Looking forward, the company will continue to adhere to the corporate strategy of "Innovation, Steady, and Progress" (守正創新, 穩中求進), and will continue to focus on the development of the company's core business. The company will continue to strengthen its research and development capabilities, and will continue to improve its product quality and service level. The company will continue to expand its market share, and will continue to increase its operating income and net profit. The company will continue to improve its financial position, and will continue to increase its cash and cash equivalents. The company will continue to strengthen its capital reserves, and will continue to increase its total liabilities and equity. The company will continue to improve its total shareholders' equity, and will continue to increase its total comprehensive income. The company will continue to improve its total comprehensive income attributable to shareholders, and will continue to increase its total comprehensive income attributable to non-controlling interests. The company will continue to improve its total comprehensive income, and will continue to increase its total comprehensive income attributable to shareholders and non-controlling interests.

Management Discussion and Analysis

Financial Results

Our company's net profit attributable to shareholders for the first half of 2023 was RMB777.9 million, an increase of 5.4% compared to RMB728.7 million for the first half of 2022. As of June 30, 2023, the company's net assets attributable to shareholders were RMB201.5 million, an increase of 1.9% compared to RMB200.0 million for the same period in 2022. The company's operating income for the first half of 2023 was RMB43.8 million, an increase of 12.8% compared to RMB42.3 million for the same period in 2022.

Revenue and Cost of Revenue

Our company's revenue for the first half of 2023 was RMB1,000.0 million, an increase of 10.0% compared to RMB909.1 million for the same period in 2022. The company's cost of revenue for the first half of 2023 was RMB956.2 million, an increase of 10.0% compared to RMB865.4 million for the same period in 2022.

	Financial Results for the period ended June 30,	
	2023	2022
	(RMB'000)	(RMB'000)
	(U. audited)	(U. audited)
Revenue	728,692	683,079
Cost of revenue	46,375	51,809
Operating income	2,858	3,417
Total revenue	777,925	738,305

Ma. age e.† ~~_____~~ . a. d A. a. ~~_____~~
$$R \quad / \quad - \quad - \quad / \quad - \quad - \quad - \quad , \quad n$$

R / - - - - - (B l . g R e e . u e) n / - - - - - /
/ n G - , / - - - - - , n n - / / - - - - - n n /
/ n , / - - - - - - - - - - - - - - - / - / - - - - - n G - , /
/ - / . n -
/ / n / - / - n G - .

n — — — — — n $\times$ — — — — — n B R / — — — — — n G — — — — — n — — — — —
 / — — — — — n — — — — — n

For the year ended June 30,	
2023	2022
(RMB'000)	(RMB'000)
(Unaudited)	(Unaudited)

B	R /	- -	/ n		744,197	689,629
L :	/		/		5,306	2,440
	- -	- -	/ (1)		10,199	4,110
R /	- -	- -	/ n		728,692	683,079

$$N_- :$$

(1) L - - - - - / - - - - - n - - - - - / - - - - - n G -
- - - - - / - - - - - / - - - - - n - - - - - / - - - - - n
- - - - - n - - - - - / - - - - - / - - - - - n - - - - - / (n Patient Need)
/ - - - - -

Fund Return Performance Graph: Based on the Fund's performance relative to its benchmark, the fund has underperformed by 7.9% over the period from January 1, 2022, to December 31, 2022.

D n R - P -, - - - - , / - / - RMB10.2 - ,
- RMB6.1 - - , 0 0 - 0 - - 2022.

Management Discussion and Analysis

During the reporting period, the Company's management has been fully aware of the importance of the Company's financial position and has taken effective measures to improve the Company's financial position.

Financial Statement as of June 30, 2023
(RMB'000)
(Unaudited)

Financial Statement as of June 30, 2022
(RMB'000)
(Audited)

Total expenditure on healthcare services		
R /	587,219	542,043
C - /	400,882	365,916
G -	186,337	176,127
Pharmaceuticals		
R /	156,978	147,586
C - /	146,610	136,141
G -	10,368	11,445
Other expenses		
R /	744,197	689,629
C - /	547,492	502,057
G -	196,705	187,572

During the reporting period, the Company's management has been fully aware of the importance of the Company's financial position and has taken effective measures to improve the Company's financial position.

The Company's management has been fully aware of the importance of the Company's financial position and has taken effective measures to improve the Company's financial position.

The Company's management has been fully aware of the importance of the Company's financial position and has taken effective measures to improve the Company's financial position.

Management Discussion and Analysis

Management Discussion and Analysis is a part of the Company's financial statements, which is prepared by the Company's management and audited by the Company's independent audit firm.

For the period ended June 30,
2023 2022
(U. audited) (, ,)

Income

Income	10,578	9,558
Expenses	1,914,618	1,729,998
(%)	84.0	87.0
Net income	1,607,422	1,505,499
(RMB'000)	553,572	513,773
After		
(RMB)	345	341
Profit	84,197	74,837
After	52	50
Total income, expense (RMB'000)	637,769	588,610

Total management expenses (RMB) 397 391

Other income

Net income	250,648	225,032
(RMB'000)	33,647	28,271
After		
(RMB)	134	126
Profit	72,781	72,748
After	291	323
Total other income, expense (RMB'000)	106,428	101,019

Total management expenses (RMB) 425 449

Total management expenses (RMB'000) 587,219 542,044

Total management expenses (RMB'000) 156,978 147,585

Management Discussion and Analysis

During the reporting period, the Company's operating income was RMB637.8 million, an increase of 8.4% compared with the same period of 2022, and the net profit was RMB106.4 million, an increase of 5.4% compared with the same period of 2022. The Company's operating profit margin was 16.5%, an increase of 0.8 percentage points compared with the same period of 2022. The Company's net profit margin was 16.7%, an increase of 0.9 percentage points compared with the same period of 2022. The Company's operating profit margin and net profit margin were both higher than the industry average level.

During the reporting period, the Company's operating income was RMB106.4 million, an increase of 5.4% compared with the same period of 2022, and the net profit was RMB106.4 million, an increase of 5.4% compared with the same period of 2022. The Company's operating profit margin was 16.5%, an increase of 0.8 percentage points compared with the same period of 2022. The Company's net profit margin was 16.7%, an increase of 0.9 percentage points compared with the same period of 2022. The Company's operating profit margin and net profit margin were both higher than the industry average level.

During the reporting period, the Company's operating income was RMB106.4 million, an increase of 5.4% compared with the same period of 2022, and the net profit was RMB106.4 million, an increase of 5.4% compared with the same period of 2022. The Company's operating profit margin was 16.5%, an increase of 0.8 percentage points compared with the same period of 2022. The Company's net profit margin was 16.7%, an increase of 0.9 percentage points compared with the same period of 2022. The Company's operating profit margin and net profit margin were both higher than the industry average level.

During the reporting period, the Company's operating income was RMB106.4 million, an increase of 5.4% compared with the same period of 2022, and the net profit was RMB106.4 million, an increase of 5.4% compared with the same period of 2022. The Company's operating profit margin was 16.5%, an increase of 0.8 percentage points compared with the same period of 2022. The Company's net profit margin was 16.7%, an increase of 0.9 percentage points compared with the same period of 2022. The Company's operating profit margin and net profit margin were both higher than the industry average level.

For the reporting period ended June 30,

2023 (RMB'000) (U. audited)	2022 (RMB'000)
-----------------------------------	-------------------

Prepaid expenses	188,867	173,660
Other receivables	208,780	179,347
Due from related parties	17,993	19,839
Due from other parties	49,033	50,657
Contract assets	32,373	28,668
Other assets	10,630	11,798
Other non-current assets	39,816	38,088

2023 (RMB'000) (U. audited)	2022 (RMB'000)
547,492	502,057

Management Discussion and Analysis

During the reporting period, the Company's operating income was RMB547.5 million, an increase of 9.0% compared with the same period of 2022. The operating profit was RMB181.2 million, an increase of 0.1% compared with the same period of 2022. The net profit was RMB164.4 million, an increase of 16.4% compared with the same period of 2022. The basic earnings per share was RMB1.64, an increase of 16.4% compared with the same period of 2022. The diluted earnings per share was RMB1.64, an increase of 16.4% compared with the same period of 2022.

The Company's operating income was RMB547.5 million, an increase of 9.0% compared with the same period of 2022. The operating profit was RMB181.2 million, an increase of 0.1% compared with the same period of 2022. The net profit was RMB164.4 million, an increase of 16.4% compared with the same period of 2022. The basic earnings per share was RMB1.64, an increase of 16.4% compared with the same period of 2022. The diluted earnings per share was RMB1.64, an increase of 16.4% compared with the same period of 2022.

The Company's operating income was RMB547.5 million, an increase of 9.0% compared with the same period of 2022. The operating profit was RMB181.2 million, an increase of 0.1% compared with the same period of 2022. The net profit was RMB164.4 million, an increase of 16.4% compared with the same period of 2022. The basic earnings per share was RMB1.64, an increase of 16.4% compared with the same period of 2022. The diluted earnings per share was RMB1.64, an increase of 16.4% compared with the same period of 2022.

Operating Profit and Operating Profit Margin

During the reporting period, the Company's operating profit was RMB181.2 million, an increase of 0.1% compared with the same period of 2022. The operating profit margin was 33.1%, an increase of 0.1 percentage points compared with the same period of 2022. The net profit was RMB164.4 million, an increase of 16.4% compared with the same period of 2022. The basic earnings per share was RMB1.64, an increase of 16.4% compared with the same period of 2022. The diluted earnings per share was RMB1.64, an increase of 16.4% compared with the same period of 2022.

For the period ended June 30,
2023
(U. audited) 2022
(U. audited)

Operating Profit	29.9%	31.7%
Operating Profit Margin	6.6%	7.8%
Operating Profit	24.9%	26.5%
Operating Profit	41.3%	30.3%
Operating Profit	25.9%	26.8%

Management Discussion and Analysis

During the reporting period, the Company's operating income increased by 25.9% (compared to the same period last year, 2022: 26.8%), and the net profit increased by 1.8% (compared to the same period last year, 2022: 1.2%).

Tax and Subsidy

During the reporting period, the Company's tax expense was RMB2.8 million (compared to the same period last year, 2022: RMB2.0 million).

Selling Expenses

During the reporting period, the Company's selling expenses were RMB7.8 million (compared to the same period last year, 2022: RMB6.1 million). The selling expenses increased by 1.1% (compared to the same period last year, 2022: 0.9%).

Administrative Expenses

During the reporting period, the Company's administrative expenses were RMB101.9 million (compared to the same period last year, 2022: RMB94.9 million). The administrative expenses increased by 7.4% (compared to the same period last year, 2022: 7.4%).

Financial Expenses
2023 2022
(RMB'000) (RMB'000)
(Unaudited) (Unaudited)

Interest income	55,922	52,917
Interest expense	13,474	11,246
Other income	14,377	12,309
Other expense	2,071	1,724
Other	16,080	16,698

Total administrative expenses 101,924 94,894

During the reporting period, the Company's administrative expenses were RMB101.9 million (compared to the same period last year, 2022: RMB94.9 million). The administrative expenses increased by 7.4% (compared to the same period last year, 2022: 7.4%).

Management Discussion and Analysis

Research and Development Expenses

During the reporting period, the R&D expenses of the Company were RMB14,958 thousand, an increase of 2.1% compared with RMB15,062 thousand in the same period of the previous year. The increase was mainly due to the increase in the number of R&D personnel and the increase in the number of R&D projects.

For the period ended June 30,

	2023 (RMB'000) (Unaudited)	2022 (RMB'000)
Cost of materials	9,691	9,646
Salaries and wages of R&D personnel	3,259	3,535
Cost of depreciation and amortization	1,982	1,868
Others	26	13
Total	14,958	15,062

During the reporting period, the R&D expenses of the Company were RMB14,958 thousand, an increase of 2.1% compared with RMB15,062 thousand in the same period of the previous year. The increase was mainly due to the increase in the number of R&D personnel and the increase in the number of R&D projects. The R&D expenses of the Company were RMB15.0 million in the same period of the previous year, an increase of 2.1% compared with RMB15.1 million in the same period of the previous year. The increase was mainly due to the increase in the number of R&D personnel and the increase in the number of R&D projects.

F. a. ce E Ne

F, the	the	ded Ju. e 30,
2023		2022
(RMB'000)		(RMB'000)
(U. audited)		(, ,)

D 年 R 月 P 日, 年 G 月 RMB20.2 元, 年 RMB1.5 元, 年 2022, 年 9.2% 年 2022, 年 RMB2.2 元, 年 2022.

Management Discussion and Analysis

1. Overview

On July 31, 2023, the Company's net assets were RMB1,393,000, and the net assets were RMB1,672,000 as of July 31, 2022.

	Financial Statement ended June 30,	
	2023	2022
	(RMB'000) (U. audited)	(RMB'000) ()
Net assets	-158	-1,672
G	-38	1,393
	-196	-279

The Company's net assets were RMB0.2 million as of July 31, 2023, and RMB0.2 million as of July 31, 2022.

Capital and Liabilities

The Company's net assets were RMB3.0 million as of July 31, 2023, and RMB2.7 million as of July 31, 2022.

Management Discussion and Analysis

Non-current Assets and Non-current Liabilities

On December 31, 2023, the Company's non-current assets and non-current liabilities were as follows:

	For the period ended June 30, 2023 (RMB'000) (Unaudited)	For the period ended June 30, 2022 (RMB'000)
Goodwill	232	1,167
Long-term receivables	5,574	4,018
Other non-current assets	119	167
Non-current assets	5,925	5,352
Long-term payables	92	239
Long-term debt	1,235	1,419
Deferred income	370	1,237
Other non-current liabilities	518	478
Non-current liabilities	2,215	3,373

During the reporting period, the Company's goodwill decreased by RMB5.9 million, mainly due to the impairment of goodwill of RMB0.6 million. The long-term receivables increased by RMB1.6 million, mainly due to the increase in the long-term receivables of RMB2.2 million. The long-term payables decreased by RMB0.9 million, mainly due to the decrease in the long-term payables of RMB0.9 million.

Income Tax Expense

During the reporting period, the Company's income tax expense was RMB11.5 million, which was 39.9% of the accounting profit for the period ended June 30, 2022. The income tax expense for the period ended June 30, 2022, was RMB19.1 million, which was 19.1% of the accounting profit for the period ended June 30, 2022.

Management Discussion and Analysis

Fund Performance

1. Net Income

As of June 30, 2023, the net income of the Company was RMB54.8 million (compared with RMB58.3 million as of June 30, 2022), an increase of 5.99%.

Accounts Receivable

As of June 30, 2023, the accounts receivable of the Company was RMB400.8 million (compared with RMB382.8 million as of June 30, 2022), an increase of 4.7%. The increase was mainly due to the increase in the number of patients and the corresponding increase in the accounts receivable.

The average number of days for the Company to collect accounts receivable was 91 days (compared with 90 days as of June 30, 2022).

Other Receivables and Prepaid Expenses

As of June 30, 2023, the other receivables and prepaid expenses of the Company were RMB97.4 million (compared with RMB69.4 million as of June 30, 2022).

Other Non-current Financial Assets

As of June 30, 2023, the other non-current financial assets of the Company were RMB63.1 million (compared with RMB63.1 million as of June 30, 2022).

Contract Liabilities

As of June 30, 2023, the contract liabilities of the Company were RMB221.9 million (compared with RMB152.5 million as of June 30, 2022). The increase was mainly due to the increase in the number of patients and the corresponding increase in the contract liabilities. The increase was mainly due to the increase in the number of patients and the corresponding increase in the contract liabilities.

Right-of-use Assets

As of June 30, 2023, the right-of-use assets of the Company were RMB169.0 million (compared with RMB190.4 million as of June 30, 2022).

Accounts Payable

As of June 30, 2023, the accounts payable of the Company were RMB88.1 million (compared with RMB85.8 million as of June 30, 2022).

Management Discussion and Analysis

Receivables, Advances and Contract Liabilities

As of June 30, 2023, the Company's receivables, advances and contract liabilities were RMB37.9 million (December 31, 2022: RMB29.9 million).

Other Payables

As of June 30, 2023, the Company's other payables were RMB87.3 million (December 31, 2022: RMB72.2 million), of which the payable for COVID-19 was RMB23.3 million.

Liabilities, Capital and Equity

The Company's liabilities, capital and equity are as follows:

	Financial Statement ended June 30,	
	2023	2022
	(RMB'000)	(RMB'000)
	(U. audited)	(U. audited)
Non-current liabilities	113,591	55,974
Current liabilities	-119,122	-164,454
Capital	9,790	194,881
Equity	4,273	86,446

Net Gain Generated from Operating Activities

During the reporting period, the Company's net gain generated from operating activities was RMB113.6 million, compared with RMB48.7 million in the same period of 2022. The net gain generated from operating activities was RMB3.0 million in the same period of 2022. The net gain generated from operating activities was RMB81.2 million in the same period of 2022. The net gain generated from operating activities was RMB33.5 million in the same period of 2022.

Net Gain Used in Investing Activities

During the reporting period, the Company's net gain used in investing activities was RMB119.1 million, compared with RMB107.8 million in the same period of 2022. The net gain used in investing activities was RMB107.8 million in the same period of 2022. The net gain used in investing activities was RMB107.8 million in the same period of 2022. The net gain used in investing activities was RMB107.8 million in the same period of 2022.

Manage et ~~_____~~ , a. d A. a' ~~_____~~

Ne. G. a. h. Ge. e. a. e. d. f. F. a. a. g. A. d. i. n. e.

D n R - P - , n / - - RMB9.8 - .

Significantly different, $P < 0.05$, according to Duncan's multiple range test.

n G _ n / - / , - - / - - n - n / , J 30, 2023.

A = n, - n, - , n G = , - / n n - - n B = ,

Ba. B u l . g a r i j a

A _ J 30, 2023, n _ _ _ _ _ n G _ _ _ _ RMB757.9 _ (_ D
31, 2022: RMB616.5 _), _ _ _ _ _ RMB109.6 _ ,
_ _ _ _ RMB251.0 _ , n R _ P _ .

C .nī . ge.n̄ Ḥ ab n̄

A - J 30, 2023, n G - n / - - n - / - n

~~And~~ P edge

D n R - -, n G - n K H- / - n
Q n L D N.. 826751, Q n L D N.. 826750, n (2016)
n R E R n N.. 0010144, n (2016) n R E R n N.. 0010142, / n (2021)
n R E R n N.. 0081628, - C n CI IC B n O n - n - - - -
A - J 30, 2023, n - n / - RMB261.0 -

Lead Lab Time

本公司于2023年6月30日，按照《企业会计准则》的规定，将外币货币性资产和负债按照即期汇率折算为人民币金额。

Management Discussion and Analysis

Financial Review

For the period from January 1 to December 31, 2023, the Company's financial performance is summarized as follows:

Exchange Rate Fluctuation and Exchange Rate

The Company's financial statements are presented in RMB. The exchange rate of the Hong Kong Dollar (HKD) to the RMB is as follows:

On December 31, 2023, the exchange rate of the Hong Kong Dollar (HKD) to the RMB is 1 HKD = 0.81 RMB. The exchange rate of the Hong Kong Dollar (HKD) to the RMB is 1 HKD = 0.81 RMB.

Geographical Area

As of December 31, 2023, the Company's revenue is derived from the following geographical areas: (1) Mainland China: 49.6% (December 31, 2022: 49.7%),

Revenue and Profit

As of December 31, 2023, the Company's revenue is 4,652 million RMB (December 31, 2022: 4,381 million RMB). The Company's profit is 125.3 million RMB (December 31, 2022: 125.3 million RMB). The Company's revenue is derived from the following geographical areas: (1) Mainland China: 49.6% (December 31, 2022: 49.7%),

Manage et ~~_____~~ , a. d A. a' ~~_____~~

E. ut l. centri e Sche e

I - - n - - n G - , n C-
n E I / 2018 - n K H- C-, L. . 《温州康寧醫院股份
有限公司2018年股權激勵計劃》, n E. u l. ce. e Sche e), n n - / / - / / - /
n - n C- - n 2017 n n n - / / - J 13, 2018. I - -
n - n n C- - n - A - n ,
- J 24, 2021, n - - n - n E I / 2018 - / / - /
(- - n) n - n B- , / / - n -
n C- ' - - n n - / / n - n E I / 2018 -
- n , / / - n n / n - n / / n -
- n C- , M 29, 2018, n - n C- , M 30, 2018, n -
n C- , M 14, 2021, n - - n C- , J 18, 2021 / n -
n C- , J 25, 2021.

I	-	n E		/		, n	-	n	-	/	-	-	165	-	,	n
1,818,529	/	n		.	.	n	-	n	-	/	n	-	n	-	-	23
-	,	n	180,516	/	n	.	.	n	(	/	-	-	) -	n	n,	n
-		/	-	-	13	-	,	n	540,229	/	n	.	A	-	n	- ,
-	-	8		/	-	-	/	-	-	-	79,274	/	n	.	A	- n
n		-	n		/	n	E		/			-	/	193	- , /	2,460,000
n	n	/.		/	-	.	n	/	n	/	-	/	-	3.2976%	- n	-
-	n C-	-	n	/	-	n	-	.	n	/	n	-	x	/	-	48
-	n	/	-	n	,	/	n	RMB10.47/	n .							

n , $-n \in \mathbb{N}$, $1 \leq n$, $-n \leq -1$:

(1) P —

n E I / ~~1~~ n - n - - / - - - / - n
 C_ , n / - n C_ ' - - / / n ,
 - / - - / - - , - n n / ,
 / n - n - - / , n n -
 - n G_ , / ~~1~~ n_ ' , n C_ '
 - n - n n x - - n C_ ' - / -
 n - n C_ ' / - / - n E I /
~~1~~ n / / - n - - ~~1~~ n_ ' - n
 - - - - - / - n / ,
 / - - - - n C_ L / n A - A -

Management Discussion and Analysis

(2) Profitability

(1) Profitability

As of the end of the reporting period, the company's operating income was 1,014,000,000 yuan, an increase of 10.14% over the same period last year. The company's operating profit was 1,014,000,000 yuan, an increase of 10.14% over the same period last year.

The company's profit before income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year. The company's profit after income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year. The company's profit after income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year.

(2) Profitability

The company's profit before income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year. The company's profit after income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year.

(3) Profitability

(1) Profitability

The company's profit before income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year. The company's profit after income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year. The company's profit after income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year.

(2) Profitability

The company's profit before income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year. The company's profit after income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year.

(3) Profitability

The company's profit before income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year. The company's profit after income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year. The company's profit after income tax was 1,014,000,000 yuan, an increase of 10.14% over the same period last year.

Management Discussion and Analysis

(4) Financial Results and Financial Position

(i) Financial Results

The Company's financial results for the period from January 1 to December 31, 2022, are as follows (in RMB million):

Item	2022	2021
Total Revenue	10,123.45	9,876.54
Total Expenses	8,765.43	8,543.21
Net Profit	1,358.02	1,333.33

(ii) Financial Position

The Company's financial position at the end of the reporting period is as follows (in RMB million):

Item	2022	2021
Total Assets	12,345.67	11,234.56
Total Liabilities	7,654.32	6,543.21
Equity	4,691.35	4,691.35

(iii) Cash Flow

The Company's cash flow for the period from January 1 to December 31, 2022, is as follows (in RMB million):

Item	2022	2021
Cash Flow from Operating Activities	1,234.56	1,123.45
Cash Flow from Investing Activities	(567.89)	(456.78)
Cash Flow from Financing Activities	345.67	234.56
Net Change in Cash	1,012.34	891.23

(5) Management Discussion and Analysis

The Company's management discussion and analysis for the period from January 1 to December 31, 2022, is as follows:

(i) Business Overview

(ii) Financial Results

(iii) Financial Position

(iv) Cash Flow

Management Discussion and Analysis

(6) The Company's...
() The Company's... RMB10.47...
() The Company's...
The Company's... RMB10.47...
() The Company's... (重點激勵、有效激勵) ...
() The Company's... (J. M. 29, 2018), ... HK\$40.00 ... RMB32.50 ...
() The Company's...
() The Company's... 32.22% ... RMB10.47 ...
The Company's... J. 30, 2023, ...

Name of Shareholder	Date of Acquisition (HKD)	Price Paid (HKD)	Date of Acquisition (RMB)	Price Paid (RMB)	Number of Shares Acquired	Total Cost of Acquisition (RMB)	Date of Acquisition	Number of Shares Held at the End of the Reporting Period	Total Cost of Acquisition (RMB)
M. ANG L	J. 18, 2021	35.95	J. 28, 2022	10.47		248,328			
M. IE	J. 18, 2021	35.95	J. 28, 2022	10.47		4,776			

Ma. age e.† ~~_____~~ . a. d A. a. ~~_____~~[illegible]

E $\rightarrow$ ~~ee~~ T, a. i. g P, g, a

Differences in the number of people who have been vaccinated against COVID-19 in the United States and the United Kingdom are shown in the following table. The data are based on the number of people who have been vaccinated as of March 1, 2022.

CORPORA E GOVERNANCE

COMPLIANCE I H HE MODEL CODE

[illegible]

ACCOUNTING STANDARD

$n_C = n_A + n_B + n_E$

2017, $n_A = 622$, $n_B = 1$, $n_E = 1$

- H. K.) (n C f a c e O. d. a ce).

CONTENTS

ACCOUNTING POLICIES

The Company has adopted the accounting policies of the People's Republic of China (the PRC) in accordance with the Accounting Standards for Enterprises issued by the Ministry of Finance of the PRC (the Ministry of Finance) on July 1, 2006.

The Company has adopted the accounting policies of the People's Republic of China (the PRC) in accordance with the Accounting Standards for Enterprises issued by the Ministry of Finance of the PRC (the Ministry of Finance) on July 1, 2006. The Company has also adopted the accounting policies of the People's Republic of China (the PRC) in accordance with the Accounting Standards for Enterprises issued by the Ministry of Finance of the PRC (the Ministry of Finance) on July 1, 2006.

The Company has adopted the accounting policies of the People's Republic of China (the PRC) in accordance with the Accounting Standards for Enterprises issued by the Ministry of Finance of the PRC (the Ministry of Finance) on July 1, 2006. The Company has also adopted the accounting policies of the People's Republic of China (the PRC) in accordance with the Accounting Standards for Enterprises issued by the Ministry of Finance of the PRC (the Ministry of Finance) on July 1, 2006.

ADDITIONAL INFORMATION OF THE INTERIM REPORT AND THE INTERIM REPORT

The Company has adopted the accounting policies of the People's Republic of China (the PRC) in accordance with the Accounting Standards for Enterprises issued by the Ministry of Finance of the PRC (the Ministry of Finance) on July 1, 2006. The Company has also adopted the accounting policies of the People's Republic of China (the PRC) in accordance with the Accounting Standards for Enterprises issued by the Ministry of Finance of the PRC (the Ministry of Finance) on July 1, 2006.

INTERIM DIVIDEND

The Board of Directors of the Company has proposed a dividend of RMB7,460,300 (RMB7,460,300) for the period from January 1, 2023, to December 31, 2023, based on the total number of shares outstanding at the end of the period. The dividend is subject to the approval of the shareholders at the annual general meeting. The dividend is subject to the approval of the shareholders at the annual general meeting.

C, a e G e, a ce a d O he, l f, a i .

... n ... P ... I D ... n ... n ...
... n ... P ... I D ... n ... N ... 30, 2023. n
C ... n ... n ... n ...
... n H ... n ... n ...
n ... P ... I D ...

I ... n n E ... L ... n P ... ' R ... C n (中華人民共和國企業所得稅法)
... n ... J ... 1, 2008, n C ...
... 10% ...
... H ... A H ...
... HK ... L ...
...
... H ...
n ... C ...
...
... H ... n R ...
D ...

I n ... H ... H ... K ... M ...
... 10% ... n ... PRC ...
C ... 10% ...
n ... H ... 10% n
n PRC ... C ...
... 10% ... H ...
... 10% ... C ...
...
... C ... H ... K ... I ... L ... C ...
...
... 10% ... 20% n n PRC ...
... C ...
... I n ... H ...
n ... 20% n n PRC ...
... PRC ... C ...
... 20%.

C, a e G e, a. ce a. d O he, l. f, a i.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

D n R - P -, n n C- - - , / , n / , - / - / / - n

C- , / .

CHANGE IN DIRECT OR SUPERIOR AND SENIOR MANAGEMENT

O M n 10, 2023, , - n , - n n - , M. HAO , - , - , , - - / D - - n C- , n n - n R - C- , - - n N- - C- .

A n 2022 n C J 9, 2023, M. G AN M. ANG
L D n n B M. ANG J
D n n B ; M. QIN H M. LI C n n
D n n B ; M. HONG
D n n B , M. JIN L M. CHAN K H
D , D , D J 9, 2023.

O J 9, 2023, - n - - n - - , M. LI N , , - - /
D - - n C_ , n - n N_ - C_ , - n A , C_ , n
R - C_ .

Change in Director, Supervisor, and Chief Executive Officer

CHANGE IN DIRECTOR, SUPERVISOR AND CHIEF EXECUTIVE OFFICER BIOGRAPHICAL DATA

The company has no change in the number of directors, supervisors, and chief executive officers during the period from January 1, 2023 to June 30, 2023. The company has no change in the number of directors, supervisors, and chief executive officers during the period from January 1, 2023 to June 30, 2023.

Name		Main position		Responsible for		Term of office	
ANG L	Chairman	Chairman	Chairman	Chairman	Chairman	From March 2023	
ANG J	Chairman	Chairman	Chairman	Chairman	Chairman	From March 2023	
						From March 2023	
						From March 2023	
JIN H	Chairman	Chairman	Chairman	Chairman	Chairman	From June 2023	

The company has no change in the number of directors, supervisors, and chief executive officers during the period from January 1, 2023 to June 30, 2023. The company has no change in the number of directors, supervisors, and chief executive officers during the period from January 1, 2023 to June 30, 2023.

Care este cea mai mare diferență?

DISCLOSURE OF INTERESTS

Director, Superintendent and Chief Executive Officer, Security

A - J 30, 2023, n - - - - n D - , n - / - , n n / -
n C- n - , - - - - n C- - - - -
(n n - P } - n) - , - n C- , n H- K- E n -
D / - 7 , 8 - P } - n (, - - - n n / n - , - - n /
n - / - - n) , - , n C- , - 352 - n
- - - n C- , n H- K- E n - n M- C- - - :

Name of Deposit	Category	Share Type	Nature of Investment	Number of Shares	Total Value	Percentage of Total Assets	Percentage of Total Assets
M.G. AN (2)	D	Equity	B	18,350,250(L)	22,044,750(L)	39.89%	29.55%
			I	3,694,500(L)			
M. ANG L (2)	D	Equity	B	3,694,500(L)	22,044,750(L)	39.89%	29.55%
			I	18,350,250(L)			
M. ANG J	D	Equity	B	100,000(L)	100,000(L)	0.18%	0.13%
M. ANG (3)	D	Equity	I	4,540,000(L)	4,540,000(L)	8.22%	6.09%

 $N_- :$

(L) : L _ _ _

(1) $\frac{n}{74,600,300} = \frac{n}{C} = \frac{55,260,000 D}{J} = \frac{19,340,300 H}{J}$ ()

(2) M.G AN n - - M. ANG L , n - , M.G AN , n D_
n / M. ANG L , M. ANG L , n D_ n / M.G AN
/ - P | - n

(3) M. γ -n, 50% $\rightarrow$ n J E M C (L, P n) $\rightarrow$ n J
E M C (L, P n) $\rightarrow$ n J E I / P n (L, P n).
P n). n - , / - P I - n $\rightarrow$ M. γ -n, 50% $\rightarrow$ n D $\rightarrow$ n

7. J 30, 2023, n A / - n B_ / , - n D _ , n / -
 - n n / - n C_ n , - n - n , / ,
 / - n C_ - - - - - (n n - P } - n) n n
 , : () - / - n C_ , n H_ K_ E n - D / - 7 , 8 - P
 | - n (, n - - n n n D - , n / - , n n / -
 n C_ x , - n / , n - - n); () - , n x
 n C_ - 352 - n ; - () - / - n C_ , n H_ K_ E n
 - n M_ C_ .

A - J 30, 2023, n C- 336 n FO / -
n D , n - / (- n n n
D , n / - n n / n C-) n , - n n - , -
n C- , n H K E n - D / 2 , 3 P } - n FO,
5% - n / - n
n C- :

Name	Country of Shareholder	Nature of Shareholder	Number of Shares	Percentage of Shares of the Issuer	Percentage of the Circulated Shares of the Issuer
Central Rural Industry Investment Fund Co., Ltd. (中央企業鄉村產業投資基金股份有限公司)	China	B	7,466,666(L)	13.51%	10.00%
Shanghai Jinzhu Enterprise Management Center (Limited Partnership) (上海金浙企業管理中心(有限合夥)) ⁽²⁾	China	Individual	4,540,000(L)	8.22%	6.09%
FAN ₁ ⁽²⁾	China	Individual	4,540,000(L)	8.22%	6.09%
Shanghai Jinzhu ⁽²⁾	China	Individual	4,540,000(L)	8.22%	6.09%

Corporate Governance and Other Information

Name	Country of Shareholder	Nature of Shareholder	Number of Shares	Percentage of Share of the Company	Percentage of Total Issued Shares of the Company ⁽¹⁾
				Share Capital ⁽¹⁾	Share Capital ⁽¹⁾
Shanghai Jinpu Kangning Health Investment Management Co., Ltd. (上海金浦健服股權投資管理有限公司) ⁽²⁾	D	Individual	4,540,000(L)	8.22%	6.09%
Wenzhou Jinping Health Investment Partnership (Limited Partnership) (溫州金寧股權投資合夥企業(有限合夥)) ⁽²⁾	D	Business	4,540,000(L)	8.22%	6.09%
Shanghai Jinping Health Investment Partnership (Limited Partnership) (上海金寧股權投資合夥企業(有限合夥)) ⁽²⁾	D	Individual	5,785,350(L)	10.47%	7.76%
Shanghai Jinping Health Investment Partnership (Limited Partnership) (上海金寧股權投資合夥企業(有限合夥)) ⁽²⁾	D	Business	4,519,003(L)	8.18%	6.06%
Shanghai Jinping Health Investment Partnership (Limited Partnership) (上海金寧股權投資合夥企業(有限合夥)) ⁽²⁾	D	Individual	4,519,003(L)	8.18%	6.06%
LIN L (林利軍)	D	Individual	6,506,309(L)	11.77%	8.72%
Shanghai Zhengxin Valley Investment Management Co., Ltd. (上海正心谷投資管理有限公司)(Shanghai Zhengxin Valley Investment Management Co., Ltd.) ⁽⁴⁾	D	Individual	6,506,309(L)	11.77%	8.72%
Wanxin Information Technology Co., Ltd. (萬得信息技術股份有限公司)	D	Individual	3,333,000(L)	6.03%	4.47%
Shanghai Hehua Enterprise Management Center (Limited Partnership) (上海荷花緣企業管理中心(有限合夥))	D	Individual	3,333,000(L)	6.03%	4.47%
Shanghai Hehua Enterprise Management Center (Limited Partnership) (上海荷花緣企業管理中心(有限合夥))	D	Business	3,333,000(L)	6.03%	4.47%
Qingdao Jinshi Lianpu Investment Co., Ltd. (青島金石瀛沍投資有限公司) ⁽⁵⁾	D	Business	2,780,000(L)	5.03%	3.73%
Jinshi Investment Co., Ltd. (金石投資有限公司) ⁽⁵⁾	D	Individual	2,780,000(L)	5.03%	3.73%
O. M. A. / - LLC	H	Individual	1,454,000(L)	7.52%	1.95%

Name	Country of Share	Name of Shareholder	Number of Shares	At the Percentage of the Capital	At the Percentage of the Capital
				Share of the Total Issued Shares	Share Capital ⁽¹⁾
O.M.C. LLC	H.K.	IL	2,150,900(L)	11.12%	2.88%
O.M.P. M.F.L.	H.K.	B.	1,279,900(L)	6.62%	1.72%
O.M.P. II, L.P.	H.K.	B.	1,052,000(L)	5.44%	1.41%
B.C. AG	H.K.	IL	1,029,400(L)	5.32%	1.38%
O.H. (鄧海麗)	H.K.	B.	1,680,000(L)	8.69%	2.25%
ANG H. (6)	D. H.K.	B.	3,984,350(L)	10.46%	7.76%
		IL	1,801,000(L)		
		B.	309,000(L)	1.60%	0.41%

(L) : L _ _ _

(2) FAN, 50% (上海金浙企業管理中心(有限合夥)), M C (L, P) (上海金浙企業管理中心(有限合夥)), E I / P n (L, P) (溫州金寧股權投資合夥企業(有限合夥)), 33.94% n J E I / P n (L, P) (溫州金寧股權投資合夥企業(有限合夥)), n J J E I / M C, L. (上海金浦健服股權投資管理有限公司) J E I / P n (L, P), n - / - P I - n FAN, n J E M C (L, P) (上海金浙企業管理中心(有限合夥)), I / M C, L. (上海金浦健服股權投資管理有限公司) n D, n J E I / P n (L, P) (溫州金寧股權投資合夥企業(有限合夥)) n C.

(3) n L / / L.P. (上海樂進投資合夥企業(有限合夥)) n 99.99% n / / L.P. (上海
海檀英投資合夥企業(有限合夥)). n - / - P l - n n L / / L.P. (上海樂進投資合夥企業(有
限合夥)) / n D n n L / / L.P. (上海檀英投資合夥企業(有限
合夥)) n C

C, a e G e, a. ce a. d O he, l. f, a i.

- (4) 本公司與上海乾剛投資管理合夥企業(有限合夥)及上海檀英投資合夥企業(有限合夥)共同設立上海正心谷投資管理有限公司(「上海正心谷」)。上海正心谷於2015年12月15日成立，註冊資本為人民幣1,000萬元，其中本公司持有上海正心谷50.62%股權，上海乾剛投資管理合夥企業(有限合夥)持有上海正心谷37.10%股權，上海檀英投資合夥企業(有限合夥)持有上海正心谷12.28%股權。上海正心谷於2016年12月31日的資產負債表如下：
- (5) 本公司與青島金石灝汭投資有限公司(「金石灝汭」)共同設立青島金石灝汭投資有限公司(「金石灝汭」)。金石灝汭於2015年12月15日成立，註冊資本為人民幣1,000萬元，其中本公司持有金石灝汭50.62%股權，青島金石灝汭投資有限公司持有金石灝汭37.10%股權，青島金石灝汭投資有限公司持有金石灝汭12.28%股權。金石灝汭於2016年12月31日的資產負債表如下：
- (6) 本公司與ANG HUI INVESTMENT MANAGEMENT (P) LIMITED(「ANG HUI」)共同設立ANG HUI INVESTMENT MANAGEMENT (P) LIMITED(「ANG HUI」)。ANG HUI於2015年12月15日成立，註冊資本為人民幣1,000萬元，其中本公司持有ANG HUI 50.62%股權，ANG HUI INVESTMENT MANAGEMENT (P) LIMITED持有ANG HUI 37.10%股權，ANG HUI INVESTMENT MANAGEMENT (P) LIMITED持有ANG HUI 12.28%股權。ANG HUI於2016年12月31日的資產負債表如下：

1. J 30, 2023, - n x - , - n D - , - n - (- n n D - ,
 2. / - - n / - n C-) n / , - n / - n - - n
 3. - , - n n / - - , - n C- , n / - - D / - 2 , 3
 - P - - n - n n - , n x - n C- - 336 - n - .

Wei Zhukang, Graduate School of
Chongqing University
GUAN Wei

PRC
4, 2023

Currency Indexed Balance Sheet

30 June 2023
(Amount in RMB, unless otherwise specified)

ASSETS	Unit	June 30, 2023	December 31, 2022
Current Assets			
Cash and cash equivalents	()	274,955,934.62	271,094,962.97
Prepaid expenses			
Financial assets	()	10,641,026.00	10,641,026.00
Derivatives			
Net assets		1,189,300.00	
Accounts receivable	()	400,828,302.04	382,836,690.89
Receivables			
Accounts payable	()	20,409,523.35	32,201,223.97
Payables			
Receivables			
Prepaid expenses			
Other assets	()	76,961,684.60	37,195,219.68
Financial assets			
Intangible assets	()	54,773,611.48	58,331,397.37
Current assets			
Accounts receivable			
Current assets			
Other assets	()	924,988.30	752,324.77
Total current assets		840,684,370.39	793,052,845.65

Condensed Balance Sheet

30 June 2023

(Amount in RMB, unless otherwise specified)

ASSETS	Unit	June 30, 2023	December 31, 2022
Non-current assets			
Long-term receivables			
Long-term equity investments			
Long-term prepayments			
Long-term receivables	(/)	14,000,000.00	14,000,000.00
Long-term equity investments	(/)	145,369,242.92	143,546,246.10
Long-term prepayments			
Long-term receivables	(/)	63,116,852.05	63,116,852.05
Long-term equity investments	(/)	682,239,468.30	695,020,440.79
Long-term prepayments	(/)	221,901,010.33	152,497,399.68
Long-term equity investments			
Long-term equity investments	(/)	169,025,623.30	190,403,751.58
Long-term equity investments	(/)	292,999,339.13	254,684,348.50
Long-term equity investments			
Long-term equity investments	(/)	108,087,642.50	107,655,738.49
Long-term equity investments	(/)	173,956,778.60	189,586,338.87
Long-term equity investments	(/)	29,996,702.31	20,682,398.07
Long-term equity investments	(/)	2,855,658.36	13,541,047.21
Total non-current assets		1,903,548,317.80	1,844,734,561.34
Total assets		2,744,232,688.19	2,637,787,406.99

n - - - - n

L / : P n - - : H / - - :
 GUAN Wei JIN Hu WANG M. hu

Condensed Balance Sheet

30 June 2023

(RMB million)

LIABILITIES AND SHAREHOLDERS' EQUITY	Unit	June 30, 2023	December 31, 2022
Current liabilities			
Accounts payable	()	271,000,000.00	203,000,000.00
Prepaid expenses			
Other payables			
Financial liabilities	()	13,922,929.38	13,922,929.38
Deferred income			
Other non-current liabilities	()	174,060.00	997,944.00
Accounts receivable	()	88,071,694.20	85,773,061.53
Other receivables	()	37,899,303.21	29,894,836.50
Contract liabilities			
Financial liabilities			
Other non-current liabilities			
Financial liabilities			
Other non-current liabilities	(/)	62,308,900.01	70,558,349.71
Other non-current liabilities	(/)	28,695,580.66	33,507,164.16
Other non-current liabilities	(/)	87,317,078.53	72,193,729.87
Financial liabilities			
Other non-current liabilities			
Financial liabilities			
Other non-current liabilities	(/)	188,642,499.08	147,598,324.39
Other non-current liabilities			
Total current liabilities		778,032,045.07	657,446,339.54
Non-current liabilities			
Long-term debt	(/)	352,830,000.00	391,010,000.00
Other non-current liabilities			
Long-term debt	()	150,199,671.94	171,437,740.27
Other non-current liabilities	()	30,766,052.11	42,404,938.54
Long-term debt			
Other non-current liabilities			
Long-term debt	()	8,885,995.00	9,037,891.00
Other non-current liabilities	(/)	40,969,216.50	40,547,878.81
Other non-current liabilities			
Total non-current liabilities		583,650,935.55	654,438,448.62

Condensed Balance Sheet

30 June, 2023

(Amount in RMB, unless otherwise specified)

LIABILITIES AND SHAREHOLDERS' EQUITY	Unit	June 30, 2023	December 31, 2022
Total liabilities		1,361,682,980.62	1,311,884,788.16
Shareholders' equity:			
Capital	()	74,600,300.00	74,600,300.00
Other			
Intangible assets			
Patent			
Copyright	()	852,721,307.37	855,078,533.30
License			
Other			
Goodwill	()	38,399,577.13	38,399,577.13
Prepaid expenses			
Reserve	()	277,256,591.89	233,506,534.43
Total shareholders' equity		1,242,977,776.39	1,201,584,944.86
Non-current liabilities		139,571,931.18	124,317,673.97
Total shareholders' equity		1,382,549,707.57	1,325,902,618.83
Total liabilities and shareholders' equity		2,744,232,688.19	2,637,787,406.99

Amount in RMB, unless otherwise specified

L: Guan Wei P: Jin Hu H: Wang M. hu
 GUAN Wei JIN Hu WANG M. hu

Parent Company Balance Sheet

June 30, 2023
(Amount in RMB, unless otherwise specified)

ASSETS	Unit	June 30, 2023	December 31, 2022
Current Assets			
Cash and cash equivalents		136,197,518.02	90,387,144.89
Financial assets			
Derivatives			
Receivables			
Accounts receivable	()	40,879,280.87	48,279,992.16
Prepaid expenses			
Other receivables		3,655,766.84	4,108,064.74
Inventory	()	527,620,871.01	600,014,558.58
Intangible assets		12,961,317.07	10,260,922.80
Goodwill			
Long-term equity investments			
Investments in subsidiaries			
Investments in associates			
Other long-term investments			105,000.00
Total Current Assets		721,314,753.81	753,155,683.17

Page: C Page: Ba a. ce Sheet:

J 30, 2023

(A - RMB_A - n ,)

ASSETS	N.º	Jun 30, 2023	Dec 31, 2022
Non-current assets			
Dereivatives			
Other non-current assets			
Long-term investments			
Long-term receivables	()	762,632,193.31	741,962,585.53
Intangible assets		63,116,852.05	63,116,852.05
Other non-current assets			
Intangible assets			
Financial assets		294,537,762.14	300,390,487.39
Cash and cash equivalents		311,600.00	311,600.00
Prepaid expenses			
Other non-current assets			
Receivables			
Intangible assets		24,397,569.85	24,714,804.16
Derivatives			
Goodwill			
Long-term investments		18,556,785.81	20,737,641.51
Derivatives		17,215,815.65	15,529,248.15
Other non-current assets		510,550.00	7,506,300.00
Total non-current assets		1,181,279,128.81	1,174,269,518.79
Total assets		1,902,593,882.62	1,927,425,201.96

$$\cap \quad \quad \quad \cap \quad \quad \quad \cap \quad \quad \quad \cap \quad \quad \quad \cap$$

L / : P n - - : H , - - , :
GUAN Wei JIN Hu WANG M. hu

Parent Company Balance Sheet

June 30, 2023

(RMB million)

LIABILITIES AND SHAREHOLDERS' EQUITY	June 30, 2023	December 31, 2022
Current liabilities		
Accounts payable	261,000,000.00	195,000,000.00
Prepaid expenses		
Deferred revenue		
Other current liabilities		
Accounts payable	19,325,049.18	20,689,401.73
Prepaid expenses	7,759,573.57	3,299,924.90
Deferred revenue		
Other current liabilities	15,599,461.56	18,740,841.95
Accounts payable	506,033.59	597,972.12
Prepaid expenses	12,734,845.88	49,473,505.95
Deferred revenue		
Other current liabilities		
Accounts payable	130,587,500.00	91,487,500.00
Prepaid expenses		
Deferred revenue		
Other current liabilities		
Total current liabilities	447,512,463.78	379,289,146.65
Non-current liabilities		
Long-term debt	207,550,000.00	284,750,000.00
Deferred revenue		
Other non-current liabilities		
Long-term debt		
Deferred revenue		
Other non-current liabilities		
Long-term debt	18,896,791.29	25,922,687.47
Deferred revenue		
Other non-current liabilities		
Long-term debt	8,885,995.00	9,037,891.00
Deferred revenue	2,291,279.89	2,291,279.89
Other non-current liabilities		
Total non-current liabilities	237,624,066.18	322,001,858.36
Total liabilities	685,136,529.96	701,291,005.01

June 30, 2023

(Amount in RMB, unless otherwise specified)

LIABILITIES AND SHAREHOLDERS' EQUITY	June 30, 2023	December 31, 2022
Shareholders' equity:		
Capital	74,600,300.00	74,600,300.00
Other equity:		
Capital reserve		
Capital reserve	871,230,628.64	871,230,628.64
Other equity:		
Other equity		
Other equity	38,399,577.13	38,399,577.13
Reserve	233,226,846.89	241,903,691.18
Total shareholders' equity	1,217,457,352.66	1,226,134,196.95
Total liabilities and shareholders' equity	1,902,593,882.62	1,927,425,201.96

L: GUAN Wei P: JIN Hu H: WANG M. hu

F_ n _ n , , 30 J 2023

(A - RMB, - n,)

Item	Number	Amount, rubles	Amount, rubles
I. Trade receivables		777,925,163.84	738,304,534.09
I / : R /	(/)	777,925,163.84	738,304,534.09
I -			
P -			
F / - - -			
II. Trade payables		724,044,723.76	680,267,107.96
I / : C -	(/)	576,390,595.76	540,536,166.95
F / - -			
N			
N - / - - - - /			
I - / / / / /			
R -			
/ n	(/)	2,783,861.65	2,011,207.46
/ / -	(/)	7,828,610.00	6,115,884.91
G / / / /	()	101,924,026.76	94,894,218.90
R n / / / -	()	14,957,995.63	15,061,500.46
F	()	20,159,633.96	21,648,129.28
I / : I		19,182,137.46	22,800,335.12
I -		2,704,831.09	-1,699,139.71
A / : O n -	()	5,822,495.15	5,904,642.30
I / - (- / n -)	()	-195,725.93	-278,819.93
I / : I / - - - - /		-157,522.45	-1,671,780.92
D - - - -			
n - / -			
F n (- / n -)			
G - - n / (- / n -)			
G - n / (- / n -)	(/)		30,711.64
C / - (- / n -)	(/)	-3,009,926.77	-2,731,680.33
A - (- / n -)			
G - / - - (- / n -)	(/)		389,315.92
III. Credit, transferred (to be repaid)		56,497,282.53	61,351,595.73
A / : N -	(/)	5,924,960.98	5,351,731.93
L : N -	(/)	2,215,131.37	3,372,509.74
IV. Trade receivables, transferred (to be repaid)		60,207,112.14	63,330,817.92
L : I -	()	11,477,880.07	19,110,080.19

Cash and cash equivalents

End of period: 2023-06-30
(Amount in RMB)

Item	Unit	Amount at the end of the period	Amount in million
V. Net cash and cash equivalents		48,729,232.07	44,220,737.73
(1) Cash			
1. N	()	48,729,232.07	44,220,737.73
2. N	()		
(2) Cash			

(A - RMB) - n

Item	Nature of the expenditure	Absolute amount	Amount in thousands of dollars
I. Revenue	()	176,204,799.00	185,800,099.09
L : C -	()	130,786,397.79	133,222,735.95
		140,434.74	-48,582.78
		613,098.03	880,640.77
G	/	42,010,452.24	39,050,764.01
R	n / / / -	9,690,626.11	9,645,738.48
F		8,063,326.82	7,219,501.23
I / : I		11,787,407.21	13,059,326.62
I	-	6,124,076.98	-5,997,744.74
A : O n -		1,314,851.41	3,866,983.80
I / - (- n -)	()	-775,547.72	-702,180.45
I / : I / - - - - - / - /		816,165.55	-1,296,180.45
D - - - - -			
n - / -			
G - - n /			
(- n -)			
G - n /			
(- n -)			30,711.64
C / -			
(- n -)		114,004.00	-687,255.02
A -			
(- n -)			
G - / - -			
(- n -)			
II. Other, from (to) other sources		-14,446,229.04	-1,662,438.60
A : N - -		5,600,210.07	3,901,067.52
L : N - -		1,517,392.82	1,964,267.50
III. Total, from (to) other sources		-10,363,411.79	274,361.42
L : I -		-1,686,567.50	-1,561,315.18
IV. Net, from (to) other sources		-8,676,844.29	1,835,676.60
() N - - - - - (- n -)		-8,676,844.29	1,835,676.60
() N - - / - / - - (- n -)			

Parent Company Interim Statement

From January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

Item	Number	Amount, RMB	Amount, USD
V. Other comprehensive income			
() Other comprehensive income			
1. Change in net defined pension plan liability			
2. Change in net defined pension plan liability			
3. Change in net defined pension plan liability			
4. Change in net defined pension plan liability			
() Other comprehensive income			
1. Other comprehensive income			
2. Change in net defined pension plan liability			
3. Change in net defined pension plan liability			
4. Change in net defined pension plan liability			
5. Change in net defined pension plan liability			
6. Change in net defined pension plan liability			
7. Other comprehensive income			
VI. Tax expense		-8,676,844.29	1,835,676.60
VII. Earnings before income tax			
() Before income tax (RMB)			
() Before income tax (RMB)			

Amount in RMB, unless otherwise specified

L: GUAN Wei P: JIN Hu H: WANG M. hu

Condensed Cash Flow Statement

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

Item	Amount	Amount
I. Cash flow from operating activities		
Cash received from sales of goods and services	780,086,767.35	653,410,155.49
Net cash received from sales of goods and services		
Cash received from interest income		
Cash received from dividends		
Cash received from other operating activities		
Net cash received from operating activities		
Cash paid for purchase of goods and services		
Net cash paid for purchase of goods and services		
Cash paid for interest expense		
Cash paid for dividends		
Cash paid for other operating activities		
Net cash paid for operating activities		
Subtotal of cash flow from operating activities	949,990,763.62	710,947,437.87
Cash flow from investing activities		
Net cash received from investing activities		
Cash received from disposal of long-term assets		
Cash received from disposal of long-term investments		
Net cash received from investing activities		
Cash paid for purchase of long-term assets		
Cash paid for purchase of long-term investments		
Net cash paid for investing activities		
Subtotal of cash flow from investing activities	300,131,941.56	267,178,624.43
Cash flow from financing activities		
Net cash received from financing activities		
Cash received from issuance of equity		
Cash received from issuance of debt		
Net cash received from financing activities		
Cash paid for repayment of debt		
Cash paid for dividend distribution		
Net cash paid for financing activities		
Subtotal of cash flow from financing activities	37,824,192.11	28,189,888.70
Net cash flow from operating activities	219,346,730.82	53,670,364.91
Subtotal of cash flow from operating activities	836,399,424.92	654,972,963.28
Net cash flow from operating activities	113,591,338.70	55,974,474.59

Continued Gain From Sale of

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

Item	Number	Amount, RMB	Amount, USD
II. Gain from sale of investment property			
Continued gain from sale of investment property		8,249,457.77	
Continued gain from sale of investment property			
Net gain from sale of investment property		26,383.01	19,038,109.95
Continued gain from sale of investment property			
Continued gain from sale of investment property		8,275,840.78	19,038,109.95
Continued gain from sale of investment property		107,843,620.41	121,119,527.96
Continued gain from sale of investment property		3,866,900.00	
Net gain from sale of investment property		15,187,013.06	62,372,716.90
Continued gain from sale of investment property		500,059.94	
Continued gain from sale of investment property		127,397,593.41	183,492,244.86
Net gain from sale of investment property		-119,121,752.63	-164,454,134.91
III. Gain from sale of financial assets			
Continued gain from sale of financial assets		2,845,000.00	4,040,100.00
Continued gain from sale of financial assets			
Continued gain from sale of financial assets		2,845,000.00	4,040,100.00
Continued gain from sale of financial assets		251,050,000.00	317,500,000.00
Continued gain from sale of financial assets			2,551,764.22
Subtotal for gain from sale of financial assets		253,895,000.00	324,091,864.22
Continued gain from sale of financial assets		109,630,000.00	87,320,000.00
Continued gain from sale of financial assets			
Continued gain from sale of financial assets		21,324,299.72	17,290,881.25
Continued gain from sale of financial assets			
Continued gain from sale of financial assets		113,150,442.74	24,599,909.22
Continued gain from sale of financial assets		244,104,742.46	129,210,790.47
Net gain from sale of financial assets		9,790,257.54	194,881,073.75

Cash Flow Statement

For the period from January 1, 2023 to June 30, 2023
(Amount in RMB, in thousands)

Item	Amount in RMB, in thousands	Amount in RMB, in thousands
IV. Effect of exchange rate changes on cash and cash equivalents	13,070.04	44,311.88
V. Net cash generated by operating activities	4,272,913.65	86,445,725.31
Amount in RMB, in thousands	258,595,990.97	188,734,845.77
VI. Cash and cash equivalents at the end of the period	262,868,904.62	275,180,571.08

Prepared by: GUAN Wei Reviewed by: JIN Hu Approved by: WANG M. hu

Parent Company Profit Statement

For the period from January 1 to June 30, 2023

(Amount in RMB, unless otherwise specified)

Item	Amount	Amount
I. Profit before tax		
Operating income	186,510,657.37	140,627,582.89
Operating expenses	491,763,058.70	259,922,752.08
Subtotal for operating profit	678,273,716.07	400,550,334.97
Operating expenses	80,195,550.90	86,999,715.12
Operating expenses	80,891,274.33	75,729,018.54
Provision for bad debts	438,877.67	3,178,776.46
Operating expenses	463,041,604.81	305,521,020.05
Subtotal for operating profit	624,567,307.71	471,428,530.17
Net profit before tax	53,706,408.36	-70,878,195.20
II. Profit after tax		
Operating income	16,657,744.50	
Operating expenses		
Net profit after tax		2,880.00
Net profit after tax		
Operating income		
Subtotal for operating profit	16,657,744.50	2,880.00
Operating expenses	1,691,749.51	4,636,366.92
Operating expenses	29,166,900.00	59,309,855.16
Net profit after tax		
Operating income		
Subtotal for operating profit	30,858,649.51	63,946,222.08
Net profit after tax	-14,200,905.01	-63,943,342.08

Parent Company Statement of Cash Flows

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

Item	Amount	Amount
III. Cash flows from operating activities		
Cash received from sales of goods and services		
Cash received from sales of goods and services	199,050,000.00	272,500,000.00
Cash received from sales of goods and services		
Cash received from sales of goods and services		
Subtotal of cash flows from operating activities	199,050,000.00	272,500,000.00
Cash received from interest and dividends	101,150,000.00	77,100,000.00
Cash received from interest and dividends		
	12,364,450.26	12,885,143.93
Interest received from bank deposits		
Cash received from bank deposits	79,243,750.00	
Subtotal of cash flows from interest and dividends	192,758,200.26	89,985,143.93
Net cash flows from operating activities	6,291,799.74	182,514,856.07
IV. Effect of exchange rate changes on cash and cash equivalents	13,070.04	44,311.88
V. Net cash and cash equivalents	45,810,373.13	47,737,630.67
Assets: Cash and cash equivalents	90,387,144.89	97,615,570.76
VI. Cash and cash equivalents at the end of the period	136,197,518.02	145,353,201.43

Prepared by: GUAN Wei Reviewed by: JIN Hu Approved by: WANG M. hu

Condensed Statement of Changes in Shareholders' Equity

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB Yuan, unless otherwise specified)

Item	Attributable to Shareholders									
	Beginning Balance	Issuance of New Shares	Repurchase of Shares	Capital Reserve	Surplus Reserve	Other Comprehensive Income	Other Reserves	Profit Before Tax	Profit After Tax	Ending Balance
I. Beginning Balance at January 1, 2023	74,600,300.00							38,889,577.13	233,506,534.43	1,325,902,618.83
II. Issuance of New Shares										
1. Issuance of New Shares		865,078,533.30						38,889,577.13	233,506,534.43	1,325,902,618.83
2. Issuance of New Shares										
3. Issuance of New Shares										
4. Issuance of New Shares										
5. Issuance of New Shares										
6. Issuance of New Shares										
III. Repurchase of Shares										
1. Repurchase of Shares										
2. Repurchase of Shares										
3. Repurchase of Shares										
4. Repurchase of Shares										
5. Repurchase of Shares										
6. Repurchase of Shares										
IV. Profit Before Tax										
1. Profit Before Tax										
2. Profit Before Tax										
3. Profit Before Tax										
4. Profit Before Tax										
5. Profit Before Tax										
6. Profit Before Tax										
V. Profit After Tax										
1. Profit After Tax										
2. Profit After Tax										
3. Profit After Tax										
4. Profit After Tax										
5. Profit After Tax										
6. Profit After Tax										
VI. Other Comprehensive Income										
1. Other Comprehensive Income										
2. Other Comprehensive Income										
3. Other Comprehensive Income										
4. Other Comprehensive Income										
5. Other Comprehensive Income										
6. Other Comprehensive Income										
VII. Ending Balance at June 30, 2023	74,600,300.00	865,078,533.30						38,889,577.13	277,256,591.89	1,382,549,707.57

GUAN Wei

JIN Hu

WANG M. hu

(A - RMB, - n,)

[illegible]

Parent Company Statement of Changes in Shareholders' Equity

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

Item	Beginning Balance					Ending Balance				
	State Capital	Reserve	Capital Reserve	Other Comprehensive Income	Surplus Reserve	Retained Earnings	Total	State Capital	Reserve	Total
I. Beginning Balance at the start of the period	74,600,300.00		871,230,628.64		38,399,577.13	241,903,691.18	1,226,134,196.95			
II. Basic Earnings										
1. Basic Earnings										
2. Other Comprehensive Income										
III. Changes in Shareholders' Equity during the period										
1. Capital Reserve										
2. Capital Reserve										
3. Capital Reserve										
4. Capital Reserve										
5. Capital Reserve										
6. Capital Reserve										
IV. Ending Balance at the end of the period	74,600,300.00		871,230,628.64		38,399,577.13	233,226,946.89	1,217,457,352.66			

GUAN Wei

JIN Hu

WANG M. hu

Parent Company Statement of Changes in Shareholders' Equity

For the period from January 1, 2023 to June 30, 2023
(Amount in RMB, unless otherwise specified)

	Beginning Balance	Issuance of New Shares	Share Repurchase	Share Split	Other Changes	Ending Balance
I. Beginning Balance at the start of the period	74,600,300.00					74,600,300.00
II. Issuance of New Shares		854,317,490.93				854,317,490.93
III. Share Repurchase						
1. Share Repurchase						
2. Share Repurchase						
3. Share Repurchase						
4. Share Repurchase						
5. Share Repurchase						
6. Share Repurchase						
IV. Ending Balance at the end of the period	74,600,300.00	854,317,490.93				928,917,790.93

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(All amounts in RMB, unless otherwise specified)

I. General Information

Wenzhou Kangning Hospital Co., Ltd. (the "Company") is a company incorporated in the People's Republic of China (the "PRC") and is a public company listed on the Shanghai Stock Exchange (the "SSE"). The Company's registered capital is RMB74,600,300.00. The Company's headquarters is located at No. 15, Wenzhou Kangning Hospital, Wenzhou City, Zhejiang Province, PRC. The Company's main business is the operation of hospitals and medical services.

On October 15, 2014, the Company was established as Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.).

The Company's fiscal year is from January 1 to December 31. On June 30, 2015, the Company's registered capital was RMB74,600,300.00.

As of June 30, 2023, the Company's registered capital was RMB74,600,300.00. The Company's main business is the operation of hospitals and medical services. The Company's headquarters is located at No. 15, Wenzhou Kangning Hospital, Wenzhou City, Zhejiang Province, PRC. The Company's main business is the operation of hospitals and medical services.

The Company's fiscal year is from January 1 to December 31, 2023.

II. Significant Accounting Policies

(I) Basis of Preparation of the Financial Statements

The Company's financial statements are prepared on the basis of the accounting principles and methods of the PRC. The Company's financial statements are prepared on the basis of the accounting principles and methods of the PRC. The Company's financial statements are prepared on the basis of the accounting principles and methods of the PRC.

The Company's financial statements are prepared on the basis of the accounting principles and methods of the PRC. The Company's financial statements are prepared on the basis of the accounting principles and methods of the PRC.

The Company's financial statements are prepared on the basis of the accounting principles and methods of the PRC. The Company's financial statements are prepared on the basis of the accounting principles and methods of the PRC.

F_ n _ n , , 30 J 2023

II. $\left(\begin{array}{cc} - & \\ - & / \end{array} \right)$

0

n
 M - F , -
 - - - n C- J 30, 2023 , n - , n -
 J - J 2023.

Ta ,categor	Ta ,ba	Ta ,de
1 - , , (A)	n A	3%, 5%, 6%, 13%
	- (, , -	
	-- , , / - n	
	) , n , - n	
	-	
	B , - A	7%
- - n	B , - A	5%
E -	B , -	15%, 20%, 25%
C -	- , / - / - -	

Tarefa	Local	Tempo
1. Análise de K	H	C, L
2. Análise de J	H	C, L
3. Análise de K	H	C, L

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

III. Significant Accounting Policies

(II) Prepayment

1. Prepayment is recognized when the company pays for goods or services in advance. It is measured at the cost of the prepayment. When the company receives the goods or services, it shall be transferred to the corresponding asset or expense account. If the prepayment is for a long-term asset, it shall be transferred to the corresponding asset account when the asset is available for use. If the prepayment is for a long-term expense, it shall be transferred to the corresponding expense account when the expense is incurred. (Refer to the Company's Accounting Policy on Prepayment, 2016 No. 36) For example, the company has prepayment for medical equipment. When the equipment is received, it shall be transferred to the fixed asset account. When the equipment is used, it shall be transferred to the depreciation expense account. (Refer to the Company's Accounting Policy on Depreciation, 2016 No. 149) For example, the company has prepayment for medical services. When the services are received, it shall be transferred to the medical expense account. When the services are used, it shall be transferred to the medical expense account. (Refer to the Company's Accounting Policy on Medical Expense, 2016 No. 35) For example, the company has prepayment for medical equipment. When the equipment is received, it shall be transferred to the fixed asset account. When the equipment is used, it shall be transferred to the depreciation expense account. (Medical Institution Business License).
2. Prepayment is recognized when the company pays for goods or services in advance. It is measured at the cost of the prepayment. When the company receives the goods or services, it shall be transferred to the corresponding asset or expense account. If the prepayment is for a long-term asset, it shall be transferred to the corresponding asset account when the asset is available for use. If the prepayment is for a long-term expense, it shall be transferred to the corresponding expense account when the expense is incurred. (Refer to the Company's Accounting Policy on Prepayment, 2016 No. 36) For example, the company has prepayment for medical equipment. When the equipment is received, it shall be transferred to the fixed asset account. When the equipment is used, it shall be transferred to the depreciation expense account. (Refer to the Company's Accounting Policy on Depreciation, 2016 No. 149) For example, the company has prepayment for medical services. When the services are received, it shall be transferred to the medical expense account. When the services are used, it shall be transferred to the medical expense account. (Refer to the Company's Accounting Policy on Medical Expense, 2016 No. 35) For example, the company has prepayment for medical equipment. When the equipment is received, it shall be transferred to the fixed asset account. When the equipment is used, it shall be transferred to the depreciation expense account. (Medical Institution Business License).
3. Prepayment is recognized when the company pays for goods or services in advance. It is measured at the cost of the prepayment. When the company receives the goods or services, it shall be transferred to the corresponding asset or expense account. If the prepayment is for a long-term asset, it shall be transferred to the corresponding asset account when the asset is available for use. If the prepayment is for a long-term expense, it shall be transferred to the corresponding expense account when the expense is incurred. (Refer to the Company's Accounting Policy on Prepayment, 2016 No. 36) For example, the company has prepayment for medical equipment. When the equipment is received, it shall be transferred to the fixed asset account. When the equipment is used, it shall be transferred to the depreciation expense account. (Refer to the Company's Accounting Policy on Depreciation, 2016 No. 149) For example, the company has prepayment for medical services. When the services are received, it shall be transferred to the medical expense account. When the services are used, it shall be transferred to the medical expense account. (Refer to the Company's Accounting Policy on Medical Expense, 2016 No. 35) For example, the company has prepayment for medical equipment. When the equipment is received, it shall be transferred to the fixed asset account. When the equipment is used, it shall be transferred to the depreciation expense account. (Medical Institution Business License).

Notes to the Financial Statements

Financial statements for the period ending June 30, 2023
(Amounts in RMB, unless otherwise specified)

1. Basis of Preparation

These financial statements have been prepared on the basis of the accounting records and other documents maintained by the Company, and are prepared in accordance with the accounting policies and accounting estimates adopted by the Company, and the accounting standards for financial statements issued by the Ministry of Finance of the People's Republic of China.

(I) Cash and Cash Equivalents

	Balance at the end of the period	Balance at the beginning of the period
Cash	209,188.36	454,907.26
Cash equivalents	262,235,513.11	257,534,338.59
Other cash equivalents	12,511,233.15	13,105,717.12

- 274,955,934.62 390,500,145.34 98,972,011.72

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(III) Accounts receivable

1. Accounts receivable

	Balance at the beginning of the period	Balance at the end of the period
Original		
- 1	409,954,541.17	388,961,193.05
1 - 2	6,077,078.96	4,755,919.87
2 - 3	3,855,479.02	3,941,367.25
Over 3	7,839,116.03	5,180,894.08
- 4	427,726,215.18	402,839,374.25
Loss: Provision for bad debts	26,897,913.14	20,002,683.36
-	400,828,302.04	382,836,690.89

2. Accounts receivable

Category	Balance at the beginning of the period				Balance at the end of the period					
	Balance		Provision for bad debts		Balance	Balance		Provision for bad debts		Balance
	Amount	P. for P. (%)	Amount	P. for P. (%)		Amount	P. for P. (%)	Amount	P. for P. (%)	
Provision for bad debts										
- 1	24,051,540.73	5.62	17,330,353.53	72.06	6,721,187.20	18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22
1 - 2										
2 - 3										
Over 3										
- 4	24,051,540.73	5.62	17,330,353.53	72.06	6,721,187.20	18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22
Provision for bad debts										
- 1	403,674,674.45	94.38	9,567,559.61	2.37	394,107,114.84	384,617,398.37	95.48	7,488,540.70	1.95	377,128,857.67
1 - 2										
2 - 3										
Over 3	403,674,674.45	94.38	9,567,559.61	2.37	394,107,114.84	384,617,398.37	95.48	7,488,540.70	1.95	377,128,857.67
-	427,726,215.18	100.00	26,897,913.14		400,828,302.04	402,839,374.25	100.00	20,002,683.36		382,836,690.89

Notes to the Financial Statements

Financial statements for the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(III) Accounts receivable (continued)

2. Accounts receivable aging schedule (continued)
Period: January 1, 2023 to June 30, 2023

Item	Balance at the end of the period			
	Balance	Provision for bad debts	Provision ratio (%)	Realized
Month-end	24,051,540.73	17,330,353.53	72.06	Provision for bad debts
-	-	-	-	L ECL
-	24,051,540.73	17,330,353.53		

Information on the provision for bad debts:

Item	Balance at the end of the period		
	Accounts receivable	Provision for bad debts	Provision ratio (%)
Original	403,674,674.45	9,567,559.61	2.37
-	403,674,674.45	9,567,559.61	

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

1. Basis of Preparation (Continued)

(III) Assets, Liabilities and Equity (Continued)

3. Prepaid Expenses (Continued)

Category	Change in the current period			
	Balance at the beginning of the period	Added during the period	Reduced during the period	Balance at the end of the period
Prepaid expenses				
Prepaid medical insurance	12,514,142.66	4,816,210.87		17,330,353.53
Prepaid property taxes	7,488,540.70	2,108,912.89	29,893.98	9,567,559.61
-	20,002,683.36	6,925,123.76	29,893.98	26,897,913.14
4. Assets (Continued)				
Assets				Assets
Assets				29,893.98

Notes to the Financial Statements

Financial statements for the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(IV) Administrative Expenses

1. Administrative Expenses

Agg	Balance at the end of the period		Balance at the end of the period	
	Amount	Percentage (%)	Amount	Percentage (%)
Jan 1	19,103,003.67	93.60	29,973,748.69	93.08
Jan 2	1,250,719.68	6.13	2,127,484.58	6.61
Jan 3	6,000.00	0.03	56,690.70	1.18
Oct 3	49,800.00	0.24	43,300.00	0.13
-	20,409,523.35	100.00	32,201,223.97	100.00

2. Administrative Expenses

Receivable from administrative expenses	Balance at the end of the period		Balance at the end of the period	
	Amount	Percentage (%)	Amount	Percentage (%)
Balance at Jan 1	4,350,000.00	21.31		
Jan 2	3,430,766.84	16.81		
Jan 3	1,762,075.01	8.63		
Jan 4	1,411,016.00	6.91		
Jan 5	1,331,110.72	6.52		
Total	12,284,968.57	60.19		

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(V) Other receivables

	Balance at the end of the reporting period	Balance at the beginning of the reporting period
1. Other receivables		
Debtors		
Others	76,961,684.60	37,195,219.68
-	76,961,684.60	37,195,219.68

1. Others

(1) Others

A	Balance at the end of the reporting period	Balance at the beginning of the reporting period
1. Others		
1.1	76,034,316.87	31,752,956.09
1.2	2,536,186.75	12,384,779.19
1.3	8,926,153.38	4,035,447.86
1.4	2,849,166.50	1,755,508.40
1.5	841,959.83	101,363.87
Others	3,876,080.95	3,877,306.68
-	95,063,864.28	53,907,362.09
Less: Provision for impairment	18,102,179.68	16,712,142.41
-	76,961,684.60	37,195,219.68

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (Continued)

(V) Other receivables (continued)

1. Other receivables (continued)
- (2) Other receivables (continued)

Category	Basis of measurement					Basis of measurement				
	Basis of measurement		Provision for bad debts			Basis of measurement		Provision for bad debts		
	Amount	Provision ratio (%)	Amount	Provision ratio (%)	Amount	Amount	Provision ratio (%)	Amount	Provision ratio (%)	Amount
Prepaid expenses	25,337,819.20	26.65	15,852,030.91	62.56	9,485,788.29	25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29
Interest receivable										
Held-to-maturity investments	25,337,819.20	26.65	15,852,030.91	62.56	9,485,788.29	25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29
Prepaid insurance	69,726,045.08	73.35	2,250,148.77	3.23	67,475,896.31	28,569,542.89	53.00	860,111.50	3.01	27,709,431.39
Prepaid interest	69,726,045.08	73.35	2,250,148.77	3.23	67,475,896.31	28,569,542.89	53.00	860,111.50	3.01	27,709,431.39
Total	95,063,864.28	100.00	18,102,179.68	/	76,961,684.60	53,907,362.09	100.00	16,712,142.41	/	37,195,219.68

Provision for bad debts is calculated based on the following method:

Name	Basis of measurement				Realized
	Amount	Provision for bad debts	Provision ratio (%)	Realized	
Held-to-maturity investments					
Lending	25,337,819.20	15,852,030.91	62.56	L	ECL
Total	25,337,819.20	15,852,030.91	/		

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(V) Other receivables (continued)

1. Other receivables (continued)
- (2) Other receivables (continued)

Particulars:

Name	Balance at the end of the period		
	Other receivables	Provision for bad debts	Provision ratio (%)
Particulars	69,726,045.08	2,250,148.77	3.23
-	69,726,045.08	2,250,148.77	

(3) Debtors

Particulars	Sage			Total
	I	II	III	
Particulars, bad debts	Life ECL			
	12-month ECL	(expected credit loss)	(expected credit loss)	
B	860,111.50		15,852,030.91	16,712,142.41
B				
-				
-				
- R /				
- R /				
P /	1,443,797.06			1,443,797.06
R /				
-				
-	53,759.79			53,759.79
O n				
B	2,250,148.77		15,852,030.91	18,102,179.68

F_ n _ n , , 30 J 2023

(A - RMB, - n,)

$$N_{\text{eff}} = n_{\text{eff}} \left(\frac{1}{3} + \frac{1}{3} \right) = \frac{2}{3} n_{\text{eff}} \quad (1)$$

(V) The, ,ece abe (c .i. ued)

1. On 1. (-)

(3) $D = \begin{pmatrix} -1 & 0 & 0 \\ 0 & -1 & 0 \\ 0 & 0 & -1 \end{pmatrix}$

$$C_n = \frac{1}{n} \sum_{i=1}^n \frac{1}{i} = \frac{1}{n} \left(1 + \frac{1}{2} + \frac{1}{3} + \dots + \frac{1}{n} \right)$$

B	aue	Stage I	Stage II	Stage III	Tota
		12- th ECL	Liabi e ECL	Liabi e ECL	
			(, ed a,ed)	(, ed a,ed)	
B	n , _ n / _	28,569,542.89		25,337,819.20	53,907,362.09
B	n , _ n / _				
	n , / / ,				
	n ,				
	- , II				
	- , III				
	- R / , II				
	- R / , I				
A	, _ _ n ,	41,156,502.19			41,156,502.19
D	_ , n ,				
O	n n				
B	n , _ n ,	69,726,045.08		25,337,819.20	95,063,864.28

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(All amounts in RMB, unless otherwise specified)

1. Basis of preparation (Continued)

(V) Other receivables (Continued)

1. Other receivables (Continued)

(4) Pursuant to the provisions of the Company's Articles of Association, the Board of Directors is authorized to decide on the disposal of other receivables within the limit of RMB 100 million.

Category	Change in the current year			
	Beginning balance	Added during the period	Reduced during the period	Ending balance
Prepaid expenses	15,852,030.91	-	-	15,852,030.91
Prepaid insurance	860,111.50	1,443,797.06	53,759.79	2,250,148.77
-	16,712,142.41	1,443,797.06	53,759.79	18,102,179.68

(5) Other receivables - related parties

	Amount
Other receivables - related parties	53,759.79

(6) Other receivables - non-related parties

Nature of receivables	Ending balance	Beginning balance
Debtors	21,148,968.11	20,677,631.31
Prepaid expenses	0.00	816,666.30
Accounts receivable	1,920,291.06	2,388,682.68
Accounts payable	38,837,819.20	26,559,018.86
Employee receivables	15,130,000.00	-
Other receivables	18,026,785.91	3,465,362.91
-	95,063,864.28	53,907,362.09

(A - RMB) - n

(VI) I, e. μ_{e}

B n , - n / -

P. / - - ,

$$0 \quad / \quad - \quad / \quad - \quad /$$

- / -

— —

B_4 /

3,697,607.74

54,633,789.63

58,331,397.37

B

1

196,008.48

269,072.88

287,243.41

752,324.77

Because of the need for the

DLc u.t

„a e, a de

14,000,000.00

14,000,000.00

Next the Florida State e

F_ n _ n , , 30 J 2023

(A - RMB) - n

1

(IX) $L \cdot g^t e_i$, $e_i u^t i$, $e_i \bar{e}_j$

1 g cañe/deq cañe. The cu, e, t e, d

	l. 28	l. 29	l. 30	l. 31	l. 32	l. 33	l. 34	l. 35	l. 36	l. 37	l. 38	l. 39	l. 40	l. 41	l. 42	l. 43	l. 44	l. 45	l. 46	l. 47	l. 48	l. 49	l. 50	l. 51	l. 52	l. 53	l. 54	l. 55	l. 56	l. 57	l. 58	l. 59	l. 60	l. 61	l. 62	l. 63	l. 64	l. 65	l. 66	l. 67	l. 68	l. 69	l. 70	l. 71	l. 72	l. 73	l. 74	l. 75	l. 76	l. 77	l. 78	l. 79	l. 80	l. 81	l. 82	l. 83	l. 84	l. 85	l. 86	l. 87	l. 88	l. 89	l. 90	l. 91	l. 92	l. 93	l. 94	l. 95	l. 96	l. 97	l. 98	l. 99	l. 100	l. 101	l. 102	l. 103	l. 104	l. 105	l. 106	l. 107	l. 108	l. 109	l. 110	l. 111	l. 112	l. 113	l. 114	l. 115	l. 116	l. 117	l. 118	l. 119	l. 120	l. 121	l. 122	l. 123	l. 124	l. 125	l. 126	l. 127	l. 128	l. 129	l. 130	l. 131	l. 132	l. 133	l. 134	l. 135	l. 136	l. 137	l. 138	l. 139	l. 140	l. 141	l. 142	l. 143	l. 144	l. 145	l. 146	l. 147	l. 148	l. 149	l. 150	l. 151	l. 152	l. 153	l. 154	l. 155	l. 156	l. 157	l. 158	l. 159	l. 160	l. 161	l. 162	l. 163	l. 164	l. 165	l. 166	l. 167	l. 168	l. 169	l. 170	l. 171	l. 172	l. 173	l. 174	l. 175	l. 176	l. 177	l. 178	l. 179	l. 180	l. 181	l. 182	l. 183	l. 184	l. 185	l. 186	l. 187	l. 188	l. 189	l. 190	l. 191	l. 192	l. 193	l. 194	l. 195	l. 196	l. 197	l. 198	l. 199	l. 200	l. 201	l. 202	l. 203	l. 204	l. 205	l. 206	l. 207	l. 208	l. 209	l. 210	l. 211	l. 212	l. 213	l. 214	l. 215	l. 216	l. 217	l. 218	l. 219	l. 220	l. 221	l. 222	l. 223	l. 224	l. 225	l. 226	l. 227	l. 228	l. 229	l. 230	l. 231	l. 232	l. 233	l. 234	l. 235	l. 236	l. 237	l. 238	l. 239	l. 240	l. 241	l. 242	l. 243	l. 244	l. 245	l. 246	l. 247	l. 248	l. 249	l. 250	l. 251	l. 252	l. 253	l. 254	l. 255	l. 256	l. 257	l. 258	l. 259	l. 260	l. 261	l. 262	l. 263	l. 264	l. 265	l. 266	l. 267	l. 268	l. 269	l. 270	l. 271	l. 272	l. 273	l. 274	l. 275	l. 276	l. 277	l. 278	l. 279	l. 280	l. 281	l. 282	l. 283	l. 284	l. 285	l. 286	l. 287	l. 288	l. 289	l. 290	l. 291	l. 292	l. 293	l. 294	l. 295	l. 296	l. 297	l. 298	l. 299	l. 300	l. 301	l. 302	l. 303	l. 304	l. 305	l. 306	l. 307	l. 308	l. 309	l. 310	l. 311	l. 312	l. 313	l. 314	l. 315	l. 316	l. 317	l. 318	l. 319	l. 320	l. 321	l. 322	l. 323	l. 324	l. 325	l. 326	l. 327	l. 328	l. 329	l. 330	l. 331	l. 332	l. 333	l. 334	l. 335	l. 336	l. 337	l. 338	l. 339	l. 340	l. 341	l. 342	l. 343	l. 344	l. 345	l. 346	l. 347	l. 348	l. 349	l. 350	l. 351	l. 352	l. 353	l. 354	l. 355	l. 356	l. 357	l. 358	l. 359	l. 360	l. 361	l. 362	l. 363	l. 364	l. 365	l. 366	l. 367	l. 368	l. 369	l. 370	l. 371	l. 372	l. 373	l. 374	l. 375	l. 376	l. 377	l. 378	l. 379	l. 380	l. 381	l. 382	l. 383	l. 384	l. 385	l. 386	l. 387	l. 388	l. 389	l. 390	l. 391	l. 392	l. 393	l. 394	l. 395	l. 396	l. 397	l. 398	l. 399	l. 400	l. 401	l. 402	l. 403	l. 404	l.
--	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	----

A.

$$H \cap A \triangleleft M,$$
$$n = C_{-}, L, 14, 179, 350, 14$$

2 L-

H _L	C _L , L _L	57,600,000.00
----------------	---------------------------------	---------------

u
H
H'

M C₊₊, L₊ 21,103,642.67

405,504.79

-65,239.09

14,584,854.93

57,534,760.91

1,313,457.77

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(X) Other Comprehensive Income

	Balance at the beginning of the period	Balance at the end of the period
For the period		
Financial assets at fair value through other comprehensive income	63,116,852.05	63,116,852.05
Other comprehensive income	63,116,852.05	63,116,852.05
-	63,116,852.05	63,116,852.05

(XI) Fixed Assets

1. Fixed Assets		
	Balance at the beginning of the period	Balance at the end of the period
For the period		
Fixed Assets	682,239,468.30	695,020,440.79
Depreciation		
-	682,239,468.30	695,020,440.79

Notes to the Financial Statement

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. The Company is a public company listed on the Shanghai Stock Exchange (600078).

(XI) Financial Instruments (continued)

2. Derivatives

Item	Budgeted		Actual		Difference		Reason		Impact	
	Amount	Unit	Amount	Unit	Amount	Unit	Amount	Unit	Amount	Unit
1. Other										
(1) B	676,374,947.03		9,403,193.79		52,160,606.66		29,771,289.75		246,930.00	
(2) I			626,942.88		7,630,725.39		1,297,900.03		4,660,269.61	
P			626,942.88		3,586,315.36		1,292,500.03		4,660,269.61	
I					4,044,410.03		5,400.00			
(3) D					930,898.70		761,455.47		1,232,965.20	
D					895,548.70		747,365.47		1,232,965.20	
D					35,350.00		14,090.00			
O			201,855.06							
(4) B	676,173,091.97		10,030,136.67		58,860,433.35		30,307,734.31		246,930.00	
2. A										
(1) B	107,334,791.37		4,981,299.30		37,252,025.00		22,455,885.36		226,919.31	
(2) I	11,430,317.32		647,131.58		5,354,862.91		1,786,678.57		6,746.45	
P	11,430,317.32		647,131.58		3,824,127.11		1,785,148.57		6,746.45	
I					1,530,735.80		1,530.00			
(3) D			2,019.60		848,466.42		705,391.14		1,180,842.38	
D					839,136.35		702,021.85		1,180,842.38	
D			2,019.60		9,330.07		3,369.29			
(4) B	118,628,103.83		5,548,993.35		41,758,421.49		23,537,172.79		233,665.76	
3. I										
(1) B										
(2) I										
(3) D										
(4) B										
4. C										
(1) C	557,544,988.14		4,481,143.32		17,102,011.86		6,770,561.52		13,264.24	
(2) C									29,887,408.04	
I	569,177,160.52		4,499,312.42		14,908,581.66		7,315,404.39		33,211,469.25	

(A - RMB, - n,)

(XII) C₂H₄Cl₂ is a green

	Balanced	Budget
Year	The first year	The second year
C_	-	-
C_	-	-
-	221,901,010.33	152,497,399.68

P, et	Baa ce a d e e d f h e e d		B n _ _ n _ /	
	B baa ce	l a, e t r, a d	B _ _	_ / _ _ _ /
n _ _ _ _ _ n				
K H _ _ _	311,600.00	311,600.00	311,600.00	311,600.00
n _ _ _ _ _ P				
C n _ _ _ _ H _	3,120,906.95	3,120,906.95		
n _ _ _ _ _ L n				
_ H _ _ _ _	84,343,864.55	84,343,864.55	72,377,326.40	72,377,326.40
n _ _ _ _ _ L n C				
H _ _ _ _ _	53,501,653.99	53,501,653.99	27,536,449.81	27,536,449.81
n _ _ _ _ _ Q n _				
H _ _ _ _ _	34,057,013.11	34,057,013.11	16,073,697.42	16,073,697.42
n _ _ _ _ _ J				
H _ _ _ _ _	45,190,609.31	45,190,609.31	35,508,167.99	35,508,167.99
O n _ _ _ _	1,375,362.42	1,375,362.42	690,158.06	690,158.06
-	221,901,010.33	221,901,010.33	152,497,399.68	152,497,399.68

Next the Florida State e

F_ n _ n , , 30 J 2023

(A - RMB_A - n ,)

[illegible]

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(XIII) Right-of-use assets

Item	Balance at the beginning of the period	Change during the period	Balance at the end of the period
1. Office buildings			
(1) Buildings	318,648,155.90		318,648,155.90
(2) Land use rights			
Land use rights			
(3) Depreciation	2,294,531.41		2,294,531.41
Depreciation	220,485.15		220,485.15
Other	2,074,046.26		2,074,046.26
(4) Balance	316,353,624.49		316,353,624.49
2. Automobiles			
(1) Automobiles	128,244,404.32		128,244,404.32
(2) Land use rights	20,598,505.54		20,598,505.54
Land use rights	20,598,505.54		20,598,505.54
(3) Depreciation	1,514,908.67		1,514,908.67
Depreciation	137,803.09		137,803.09
Other	1,377,105.58		1,377,105.58
(4) Balance	147,328,001.19		147,328,001.19
3. Intangible assets			
(1) Intangible assets			
(2) Land use rights			
(3) Depreciation			
(4) Balance			
4. Construction in progress			
(1) Construction in progress	169,025,623.30		169,025,623.30
(2) Construction in progress	190,403,751.58		190,403,751.58

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All figures in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(XIV) Intangible Assets

1. Development Costs

Item	Land use rights	Patent rights	Software	Medical device qualification	Carrying amount at the end of the reporting period		Total
					Cost	Accumulated amortization	
1. Other intangible assets							
(1) Land use rights	128,594,176.05	3,061,637.13	9,677,612.80	158,837,000.00	32,400,000.00		332,570,425.98
(2) Patents	26,368,000.00	0.00	8,990,124.81	17,000,000.00	0.00		52,358,124.81
Patent application fees	26,368,000.00	0.00	8,984,124.81	0.00	0.00		35,352,124.81
Intangible assets under development	0.00	0.00	6,000.00	17,000,000.00	0.00		17,006,000.00
(3) Software							
(4) Medical devices	154,962,176.05	3,061,637.13	18,667,737.61	175,837,000.00	32,400,000.00		384,928,550.79
2. Amortization							
(1) Land use rights	12,499,461.07	690,585.66	10,755,014.04	45,087,445.28	8,853,571.43		77,886,077.48
(2) Patents	1,783,569.95	193,534.62	2,207,803.24	8,765,369.23	1,092,857.14		14,043,134.18
Patent amortization	1,783,569.95	193,534.62	2,206,653.24	8,765,369.23	1,092,857.14		14,041,984.18
Intangible assets under development	0.00	0.00	1,150.00	0.00	0.00		1,150.00
Other intangible assets							
(3) Software							
(4) Medical devices	14,283,031.02	884,120.28	12,962,817.28	53,852,814.51	9,946,428.57		91,929,211.66
3. Impairment							
(1) Land use rights							
(2) Patents							
(3) Software							
(4) Medical devices							
4. Carrying amount at the beginning of the period							
(1) Land use rights	140,679,145.03	2,177,516.85	5,704,920.33	121,984,185.49	22,453,571.43		292,999,339.13
(2) Patents	116,094,714.98	2,371,051.47	-1,077,401.24	113,749,554.72	23,546,428.57		254,684,348.50

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (Continued)

(XV) Goodwill

1. Goodwill

Name of the addressee	At the end of the reporting period		At the beginning of the reporting period	
	Original value	Impairment loss	Original value	Impairment loss
Wenzhou Kangning Hospital Co., Ltd.	9,271,800.00		9,271,800.00	
Huizhou Kangning Hospital Co., Ltd.	690,331.47		690,331.47	
Guangzhou Kangning Hospital Co., Ltd.	1,549,022.38		1,549,022.38	
Shenzhen Kangning Hospital Co., Ltd.	7,784,850.00		7,784,850.00	
Baotou Kangning Hospital Co., Ltd.	22,987,331.04		22,987,331.04	
Nanchang Kangning Hospital Co., Ltd.	151,048.40		151,048.40	
Hubei Kangning Hospital Co., Ltd.	5,068,959.78		5,068,959.78	
Chongqing Kangning Hospital Co., Ltd.	6,843,288.91		6,843,288.91	
Henan Kangning Hospital Co., Ltd.	19,416,285.97		19,416,285.97	
Shanghai Kangning Hospital Co., Ltd.	51,770,194.67		51,770,194.67	
Hubei Kangning Hospital Co., Ltd.	1,272,643.00		1,272,643.00	
Nanchang Kangning Hospital Co., Ltd.	326,012.44		326,012.44	0.00
Jiangxi Kangning Hospital Co., Ltd.	5,060,323.85		5,060,323.85	
Henan Kangning Hospital Co., Ltd.	445,742.09		445,742.09	
Henan Kangning Hospital Co., Ltd.	312,174.36		312,174.36	
Total	132,192,091.91	757,916.45	132,192,091.91	326,012.44
Shenzhen Kangning Hospital Co., Ltd.	22,987,331.04		22,987,331.04	
Guangzhou Kangning Hospital Co., Ltd.	1,549,022.38		1,549,022.38	
Total	24,536,353.42		24,536,353.42	
Total	107,655,738.49		107,655,738.49	

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(XVI) Long-term receivables

Item	Balance at the beginning of the period	Increase during the period	Decrease during the period	Balance at the end of the period
Receivables	189,414,067.93	7,029,806.14	22,680,809.38	173,763,064.69
Long-term receivables	172,270.94	58,025.87	36,582.90	193,713.91
-	189,586,338.87	7,087,832.01	22,717,392.28	173,956,778.60

(XVII) Deferred tax assets and deferred tax liabilities

1. Deferred tax assets

Item	Balance at the beginning of the period	Change during the period	Balance at the end of the period
Deferred tax assets	17,958,526.92	3,583,328.82	16,979,155.87
Deferred tax liabilities	68,579,840.04	17,144,960.01	50,169,236.15
Deferred tax assets	4,260,552.49	1,065,138.13	4,390,510.38
Deferred tax liabilities	54,688,502.33	8,203,275.35	54,688,502.33
-	145,487,421.78	29,996,702.31	126,227,404.73

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Non-current assets (continued)

(XVII) Deferred tax assets and deferred tax liabilities (continued)

2. Deferred tax assets and liabilities

Item	Balance at the end of the reporting period		Balance at the beginning of the reporting period	
	Deferred tax assets	Deferred tax liabilities	Deferred tax assets	Deferred tax liabilities
A. Deferred tax assets				
- Income tax assets	150,226,983.03	37,556,745.76	148,564,631.76	37,141,157.94
C. Deferred tax liabilities	13,116,852.07	1,967,527.81	13,116,852.07	1,967,527.81
O. Other deferred tax assets and liabilities	5,779,771.72	1,444,942.93	6,620,111.12	1,439,193.06
-	169,123,606.82	40,969,216.50	168,301,594.95	40,547,878.81

(XVIII) Other non-current assets

Item	Balance at the end of the reporting period		Balance at the beginning of the reporting period	
	Other non-current assets	Other non-current liabilities	Other non-current assets	Other non-current liabilities
P. Other non-current assets				
- Other non-current assets	2,855,658.36	2,855,658.36	6,605,047.21	6,605,047.21
-	2,855,658.36	2,855,658.36	13,541,047.21	13,541,047.21

(XIX) Share-based payments

1. Share-based payments

Item	Balance at the end of the reporting period		Balance at the beginning of the reporting period	
	Share-based payments	Share-based payments	Share-based payments	Share-based payments
A. Share-based payments				
- Share-based payments	261,000,000.00	195,000,000.00		
G. Share-based payments	10,000,000.00	8,000,000.00		
-	271,000,000.00	203,000,000.00		

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB Yuan, unless otherwise specified)

1. Notes to the Financial Statements (Continued)

(XX) Trading Financial Instruments

Item	Balance at the beginning of the period	Change during the period	Balance at the end of the period
Trading financial instruments	13,922,929.38		13,922,929.38
	13,922,929.38		13,922,929.38

(XXI) Receivables

Item	Balance at the beginning of the period	Change during the period	Balance at the end of the period
Receivables	174,060.00		997,944.00
	174,060.00		997,944.00

(XXII) Accounts Payable

Item	Balance at the beginning of the period	Change during the period	Balance at the end of the period
Accounts payable	85,509,131.21		84,193,738.77
1-2	2,072,209.99		1,161,389.02
2-3	222,323.13		71,968.47
Other	268,029.87		345,965.27
	88,071,694.20		85,773,061.53

(XXIII) Advances

Item	Balance at the beginning of the period	Change during the period	Balance at the end of the period
Advances	37,838,350.85		29,436,207.46
Receivables	60,952.36		458,629.04
	37,899,303.21		29,894,836.50

Notes to the Financial Statement

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statement (Continued)

(XXIV) Earnings before income tax

1. Income tax expense

	Balance at the beginning of the period	Income tax expense	Income tax expense	Balance at the end of the period
	June 30, 2023	June 30, 2023	June 30, 2023	June 30, 2023
Income tax expense	68,138,710.58	276,185,318.89	284,379,644.16	59,948,544.43
Income tax expense	2,419,639.13	15,295,605.39	15,350,729.82	2,360,355.58
	70,558,349.71	291,480,924.28	299,730,373.98	62,308,900.01

2. Income tax expense

	Balance at the beginning of the period	Income tax expense	Income tax expense	Balance at the end of the period
	June 30, 2023	June 30, 2023	June 30, 2023	June 30, 2023
(1) Income tax expense	66,161,148.57	246,166,417.83	254,298,788.29	58,206,945.42
(2) Income tax expense	307,382.14	8,945,632.04	9,112,880.10	140,134.08
(3) Income tax expense	1,464,184.43	10,312,097.71	10,206,582.36	1,568,340.49
Income tax expense	1,425,747.59	9,988,211.42	9,882,046.59	1,530,027.76
Income tax expense	37,301.70	307,828.23	306,735.71	38,296.09
Income tax expense	424.64	17,392.06	17,800.06	16.64
Income tax expense	710.50	-1,334.00		
(4) Income tax expense	205,995.44	10,747,471.90	10,748,806.90	32,011.54
(5) Income tax expense		13,699.41	12,586.51	1,112.90
(6) Income tax expense				
(7) Income tax expense				
(8) Income tax expense				
	68,138,710.58	276,185,318.89	284,379,644.16	59,948,544.43

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

1. Notes to the Financial Statements (Continued)

(XXIV) Earnings before income tax

3. Loss before income tax

Item	Balance at the beginning of the period	Income tax expense	Decrease in income tax expense	Balance at the end of the period
Balance at the beginning of the period	2,347,144.91	14,797,062.82	14,853,868.77	2,286,320.08
Income tax expense	72,494.22	498,542.57	496,861.05	74,035.50
Balance at the end of the period	2,419,639.13	15,295,605.39	15,350,729.82	2,360,355.58

(XXV) Tax expense

Item	Balance at the beginning of the period	Balance at the end of the period
Income tax expense (A)	2,509,870.76	2,399,813.52
Earnings before income tax	24,032,693.09	26,859,279.46
Income tax expense	805,458.42	1,260,918.02
Prepaid income tax	986,640.62	2,292,516.47
Income tax expense	159,849.30	387,329.69
Income tax expense	26,742.20	25,663.04
Income tax expense	100,435.81	163,205.29
Earnings before income tax	71,741.82	116,587.33
Earnings before income tax	1,558.80	1,696.00
Income tax expense	589.84	155.34
Balance at the end of the period	28,695,580.66	33,507,164.16

(XXVI) Other income

Item	Balance at the beginning of the period	Balance at the end of the period
Income tax expense	577,043.05	625,181.01
Income tax expense	86,691,897.52	70,881,686.82
Income tax expense	87,317,078.53	72,193,729.87

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Non-current assets (continued)

(XXVI) Other intangible assets (continued)

1.

Item	Balance at the beginning of the period	Balance at the end of the period
	Amount	Amount
Patent	577,043.05	577,043.05
-	-	-

2.

Item	Balance at the beginning of the period	Balance at the end of the period
	Amount	Amount
Software	625,181.01	735,000.00
-	625,181.01	735,000.00

3.

Item	Balance at the beginning of the period	Balance at the end of the period
	Amount	Amount
Patent	24,580,009.11	25,932,146.03
Patent	0.00	7,000,000.00
Software	1,400,808.88	3,682,272.62
Domain name	1,905,152.80	1,900,552.80
Copyright	25,480,853.08	17,695,375.57
Patent	3,998,613.52	4,374,261.21
Other intangible assets	2,562,779.79	3,673,024.53
Other intangible assets	23,400,314.30	-
Other intangible assets	3,363,366.04	6,624,054.06
-	86,691,897.52	70,881,686.82

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

1. Non-current assets

(XXVII) Non-current assets due to the company

Item	Balance at the end of the reporting period	Balance at the beginning of the reporting period
Long-term equity investments	134,070,000.00	22,470,000.00
Long-term receivables	24,992,499.08	99,580,000.00
Long-term prepayments	29,580,000.00	25,548,324.39
-	188,642,499.08	147,598,324.39

(XXVIII) Other non-current assets

Item	Balance at the end of the reporting period	Balance at the beginning of the reporting period
Prepaid expenses	182,500,000.00	186,000,000.00
Long-term prepayments	61,500,000.00	-
Long-term receivables	242,900,000.00	227,480,000.00
Long-term prepayments	134,070,000.00	22,470,000.00
-	352,830,000.00	391,010,000.00

(XXIX) Loans receivable

Item	Balance at the end of the reporting period	Balance at the beginning of the reporting period
Long-term prepayments	150,199,671.94	171,437,740.27
-	150,199,671.94	171,437,740.27

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(Amount in RMB, unless otherwise specified)

1. Notes to the Financial Statements (Continued)

(XXX) Long-term receivables

Item	Balance at the end of the reporting period	Balance at the beginning of the reporting period
	Amount	Amount
Long-term receivables	30,766,052.11	42,404,938.54
Total	30,766,052.11	42,404,938.54

1. Long-term receivables

Item	Balance at the end of the reporting period	Balance at the beginning of the reporting period
	Amount	Amount
Financial receivables	60,346,052.11	141,984,938.54
Long-term receivables	8,333,553.62	9,382,772.07
Long-term receivables	29,580,000.00	99,580,000.00
Total	30,766,052.11	42,404,938.54

(XXXI) Deferred income

Item	Balance at the end of the reporting period	Balance at the beginning of the reporting period	Balance at the end of the reporting period	Balance at the beginning of the reporting period
	Amount	Amount	Amount	Amount
Deferred income	9,037,891.00	151,896.00	8,885,995.00	-
Total	9,037,891.00	151,896.00	8,885,995.00	-

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

1. Notes to the Financial Statements (Continued)

(XXXI) Deferred Income (Continued)

For the period from January 1, 2023 to June 30, 2023

Liabilities	Balance at the beginning of the period	Additions during the period	Deductions during the period	Balance at the end of the period	Amount in RMB
Deferred income	9,037,891.00	151,896.00		8,885,995.00	Amount in RMB
	9,037,891.00	151,896.00		8,885,995.00	

(XXXII) Share Capital

Share Capital	Balance at the beginning of the period	Increase (+) / Decrease (-) during the period		Balance at the end of the period	Amount in RMB
		Issuance of shares	Redemption of shares		
Share Capital	74,600,300.00			74,600,300.00	

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (Continued)

(XXXIII) Capital

	Balance at the beginning of the period	Issued shares	Decrease	Balance at the end of the period
Capital	783,420,735.87		2,357,225.93	781,063,509.94
Other	44,857,374.20			44,857,374.20
Other	26,800,423.23			26,800,423.23
-	855,078,533.30		2,357,225.93	852,721,307.37

(XXXIV) Share

	Balance at the beginning of the period	Issued shares	Decrease	Balance at the end of the period
Share	38,399,577.13			38,399,577.13
-	38,399,577.13			38,399,577.13

Other:

10% of the total number of shares issued by the company, the company shall have the right to purchase the shares at a price of 50% of the book value of the shares.



Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(Amount in RMB, unless otherwise specified)

1. Non-current assets (continued)

(XXXVI) Re-evaluation of intangible assets (continued)

1. Amortization of intangible assets (continued)

Balance at the beginning of the period:

	At the beginning of the reporting period	At the end of the reporting period
Intangible assets	728,692,633.43	683,078,850.17
Intangible assets: Patents	156,978,407.05	147,585,739.76
Intangible assets: Software	571,714,226.38	535,493,110.41
Intangible assets: Other intangible assets	49,232,530.41	55,225,683.92
Intangible assets: Other intangible assets	28,881,807.57	37,656,705.69
Intangible assets: Other intangible assets	1,485,148.50	1,500,000.00
Intangible assets: Other intangible assets	2,857,971.77	3,417,245.81
Intangible assets: Other intangible assets	16,007,602.57	12,651,732.42
Total	777,925,163.84	738,304,534.09

2. Depreciation of intangible assets

Depreciation of intangible assets is calculated on a straight-line basis over the expected useful life of the intangible asset. The depreciation of intangible assets is recorded as an expense in the profit and loss account.

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(XXXVII) Tax and charges

Item	Amount, the current period	Amount, the prior period
Paid	1,704,919.27	1,001,891.04
Charged	398,619.06	367,707.91
Estimated	284,861.86	261,185.58
Liability	244,228.99	244,607.61
Income	139,457.81	124,010.34
Other	11,774.66	11,804.98
-	2,783,861.65	2,011,207.46

(XXXVIII) Selling and administrative expenses

Item	Amount, the current period	Amount, the prior period
Employee	4,571,354.43	3,605,185.29
Director	96,371.80	85,032.37
Administrative	22,513.69	22,513.74
Administrative	155,131.68	134,612.88
Employee	316,393.31	730,951.48
Other	180,167.93	115,469.17
Other	167,234.65	128,719.71
Other	10,478.18	1,413.19
Other	235,841.00	9,603.00
Paid	2,020,072.51	1,177,534.61
Rent	25,268.40	78,115.93
Other	27,782.42	26,733.54
-	7,828,610.00	6,115,884.91

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

1. Notes to the Financial Statements (Continued)

(XXXIX) Government Grants

Item	Amount, the current year	Amount, the previous year
Government Grants	55,921,762.58	49,573,428.40
Government Grants	6,990,089.75	5,720,360.45
Government Grants	1,800,111.04	2,293,955.81
Government Grants	4,684,159.80	3,232,014.43
Government Grants	1,039,347.77	899,362.84
Government Grants	1,386,037.88	779,580.51
Government Grants		3,343,511.39
Government Grants	1,700,201.12	1,607,083.90
Government Grants	2,070,528.66	1,723,546.90
Government Grants	717,753.37	963,759.27
Government Grants	1,676,255.06	1,724,874.78
Government Grants	1,263,793.76	1,603,121.87
Government Grants	1,582,961.78	1,481,876.67
Government Grants	14,377,209.14	12,306,482.93
Government Grants		2,400.00
Government Grants	3,248,248.19	3,506,322.65
Government Grants	2,599,553.04	2,306,537.45
Government Grants	866,013.82	1,825,998.65
	101,924,026.76	94,894,218.90

(XL) Research and Development Expenses

Item	Amount, the current year	Amount, the previous year
Research and Development Expenses	13,998,896.69	13,219,266.23
Research and Development Expenses	191,563.81	210,371.24
Research and Development Expenses		29,160.96
Research and Development Expenses	92,076.48	293,486.60
Research and Development Expenses	1,369.72	6,962.67
Research and Development Expenses	388,988.66	598,846.70
Research and Development Expenses		28,444.60
Research and Development Expenses	285,100.27	674,961.46
	14,957,995.63	15,061,500.46

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(XLI) Financial Assets

Item	Amount, RMB	Amount, US\$
Financial assets	19,182,137.46	22,800,335.12
Financial assets at fair value through profit or loss	5,058,106.16	7,238,858.39
Loans receivable	2,704,831.09	1,699,139.71
Financial assets at amortized cost	-13,070.04	-44,311.88
Other financial assets	544,284.06	591,245.75
Total	20,159,633.96	21,648,129.28

(XLII) Financial Liabilities

Item	Amount, RMB	Amount, US\$
Financial liabilities	5,600,421.10	5,361,749.51
Financial liabilities at fair value through profit or loss	200,405.44	220,294.02
Other financial liabilities	21,668.61	321,968.77
Total	5,822,495.15	5,904,642.30

(XLIII) Financial Instruments

Item	Amount, RMB	Amount, US\$
Financial instruments at fair value through profit or loss	-157,522.45	-1,671,780.92
Financial instruments at amortized cost	-38,203.48	1,392,960.99
Total	-195,725.93	-278,819.93

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (Continued)

(XLIV) Gain from change in fair value

Source of gain from change in fair value	Amount for the current period	Amount
For the period from January 1, 2023 to June 30, 2023		30,711.64
-		30,711.64

(XLV) Change in fair value

Item	Amount for the current period	Amount
Loss from change in fair value of financial assets at fair value through profit or loss	-3,047,374.71	-3,348,573.01
Loss from change in fair value of financial assets at fair value through other comprehensive income	37,447.94	616,892.68
-	-3,009,926.77	-2,731,680.33

(XLVI) Gain from change in fair value

Item	Amount for the current period	Amount
Gain from change in fair value of financial assets at fair value through profit or loss		
(-)		
Loss from change in fair value of financial assets at fair value through other comprehensive income		
(-)		
-		

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (continued)

(XLVII) Notes to the Financial Statements

	Amount in RMB		
	At the end of the reporting period	At the end of the reporting period	At the end of the reporting period
Item	2023.6.30	2023.6.30	2023.6.30
Goodwill	10,137.96	8,843.14	10,137.96
Intangible assets	10,137.96	8,843.14	10,137.96
Development costs	5,573,844.86	4,017,521.21	5,573,844.86
Goodwill and intangible assets	232,490.00	1,166,876.42	232,490.00
Other	108,488.16	158,491.16	108,488.16
	5,924,960.98	5,351,731.93	5,924,960.98

(XLVIII) Notes to the Financial Statements

	Amount in RMB		
	At the end of the reporting period	At the end of the reporting period	At the end of the reporting period
Item	2023.6.30	2023.6.30	2023.6.30
Long-term equity investments	91,822.62	239,086.15	91,822.62
Intangible assets	91,822.62	239,086.15	91,822.62
Equity investments	1,234,751.71	1,419,258.76	1,234,751.71
Long-term equity investments	370,093.31	1,237,300.03	370,093.31
Other	518,463.73	476,864.80	518,463.73
	2,215,131.37	3,372,509.74	2,215,131.37

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements (Continued)

(XLIX) Income Statement

1. Income Statement

Item	Amount in thousands of RMB	
	2023 1-6	2022 1-6
Operating income	23,358,206.57	23,230,774.09
Operating expenses	-11,880,326.50	-4,120,693.90
Operating profit	11,477,880.07	19,110,080.19

2. Income Statement

Item	Amount in thousands of RMB	
	2023 1-6	2022 1-6
Operating income	60,207,112.14	
Operating expenses	16,067,002.03	
Operating profit	212,271.74	
Operating expenses	-1,472,685.98	
Operating profit	-768,779.98	
Operating expenses	645,141.99	
Operating profit	-1,107,566.29	
Operating expenses	-241,776.23	
Operating profit	-611,075.57	
Operating expenses	-1,336,634.41	
Operating profit	91,982.77	
Operating profit	11,477,880.07	

Next the Florida State e

F_ n _ n , , 30 J 2023

(A - RMB_A - n ,)

$$N_{\text{eff}} = n_{\text{eff}} \left(\frac{g_{\text{eff}}}{g_{\text{eff}}^{\text{ref}}} \right)^{1/4}$$

(L) $Ea_{1,1} \rightarrow g \otimes e_{1,1} a_{1,1} e$

$$1. \quad B \quad n$$
[illegible]

the ☐ the current condition / - -

C. _____

43,750,057.46	38,788,155.89
---------------	---------------

38,788,155.89

0, / - - , - /

74,600,300.00	74,600,300.00
---------------	---------------

74,600,300.00

B n

0.59

0.52

$$I \quad , \quad :B \quad \cap \quad - \quad -$$

0.59

0.52

B $n = 1, 2, \dots$

— — —

2. D , n

D , n
n n -
- C-

(), /, /, /

():

the $\mathbb{C}^n$ is the $\mathbb{C}^n$ itself, and the $\mathbb{C}^n$ is the $\mathbb{C}^n$ itself.

C. _____

43,750,057.46	38,788,155.89
---------------	---------------

38,788,155.89

$$n, \quad / \quad - \quad - \quad , \quad - \quad /$$

74.600.300.00	74.600.300.00
---------------	---------------

74.600.300.00

D

0.59

0.52

$$I \quad , \quad :D \quad , \quad n \quad -$$

0.59

0.52

D.

(A - RMB) - n

(LI) Suppose that, if, and only if, the cash flow Φ is a

Subtotal of		Actual	Actual
The currency		USD	EUR
1.	R - - - - - n - - - - -		
	N - - - - -	43,750,057.46	38,788,155.89
	A : G - - - - - n n - - -		
	C - - - - -	4,979,174.61	5,432,581.84
	P - - - - -	3,009,926.77	2,731,680.33
	D - - - - -	23,833,784.01	28,063,119.25
	D - - - - -		
	D - - - - -	20,598,505.54	20,760,704.78
	A - - - - -	14,041,984.18	12,489,361.10
	A - - - - -	22,717,392.28	25,082,357.37
	L - - - - -		
	(- - - - -)		-389,315.92
	L - - - - -		
	(- - - - -)	81,684.66	230,243.01
	L - - - - -		
	(- - - - -)		-30,711.64
	F - - - - -		
	(- - - - -)	19,169,067.42	22,756,023.24
	I - - - - -		
	(- - - - -)	195,725.93	278,819.93
	D - - - - -		
	(- - - - -)	-9,314,304.24	153,565.04
	I - - - - -		
	(- - - - -)	421,337.69	2,475,741.06
	D - - - - -		
	(- - - - -)	3,557,785.89	3,049,315.08
	D - - - - -		
	(- - - - -)	13,057,344.16	-103,135,220.95
	I - - - - -		
	(- - - - -)	-46,508,127.66	-2,761,944.82
	O n - - - - -		
	N - - - - -	113,591,338.70	55,974,474.59
2.	- - - - -		
	C - - - - -		
	C - - - - -		
	F - - - - -		
3.	N - - - - -		
	C - - - - -	262,868,904.62	275,180,570.66
	L : C - - - - -	258,595,990.97	188,734,845.35
	A : C - - - - -		
	L : C - - - - -		
	N - - - - -	4,272,913.65	86,445,725.31

[illegible]

(A - RMB, - n,)

(LIII) ~~As the~~ n~~h~~ r~~e~~ d~~ed~~ . e~~nt~~ , , ght - f~~u~~le

1. C_n — — — — —

1. B — — — — — n — —

[illegible]

Notes to the Financial Statements

Financial statements for the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Company Information

(1) Business scope and nature of the company (continued)

2. Company Information

Item	Wenzhou Kangning Hospital Co., Ltd.	Lud Kaige Kaige Hospital
	Pharmaceuticals, etc.	Medical Equipment
Capital		
Initial capital	250,000.00	15,500,000.00
Additional capital		
Capital reserve		
Surplus reserve		
Undistributed profit		
Total	250,000.00	15,500,000.00
Liabilities	-195,742.09	15,187,825.64
Guaranteed/Accrued liabilities		
Total	445,742.09	312,174.36

Equity

Capital reserve, surplus reserve, undistributed profit, etc.

(A - RMB, - n,)

(l) But, ~~the~~ c b. al ~~the~~ c c r, (c r, ued)

3. $\frac{1}{n} \rightarrow 0$, $\frac{n}{n-1} \rightarrow 1$.

Item	Wealth Accumulation		Liabilities	
	Financial Position		Financial Position	
	Value	Value	Value	Value
Assets				
Current Assets				
Cash	12,167.15	12,167.15	11,292,072.74	7,414,323.69
Other Current Assets			1,074,846.30	677,201.30
Property			1,167,668.59	166,068.59
Investments	109,424.55	109,424.55	373,931.03	373,931.03
Other Assets			360,020.26	360,020.26
Fixed Assets	8,270.20	8,270.20	2,196,970.19	2,505,404.03
Reserves				
General Reserve			82,000.00	
Other Reserves	4,850.00	4,850.00		17,000,000.00
Liabilities			5,550,629.97	5,550,629.97
Debt				
Other Debt				
Equity				
Paid-up Capital	210,741.55	210,741.55	457,516.78	457,516.78
Other Equity	1,010,178.58	109,424.55	1,045,046.80	1,045,046.80
Reserves			340,592.00	340,592.00
Other Equity	10,287.89	10,287.89		
Assets				
Liabilities				
Debt				2,987,359.95
Net Assets	-1,096,496.12	-195,742.09	20,817,970.44	29,780,050.28
Liabilities			10,200,805.52	14,592,224.64
Net Assets	-1,096,496.12	-195,742.09	10,617,164.92	15,187,825.64

D - - n / - , , : :

[illegible]

Next the Florida State e

F_ n _ n , , 30 J 2023

(A - RMB, - n,)

1. 1 - 0

(I) Inter-subject

1. $\frac{1}{2} G$

[illegible]

F_ n _ n , , 30 J 2023

(A - RMB, - n,)

(l) Interpreted as a used

1. $\frac{1}{2} G_2 = \frac{1}{2} G_2$ (-)

Name of Subsidiary		Legal form	Major shareholder	Percentage of shareholding	Shareholding ratio (%)	Method of acquisition
H K H L C., L.	LLC	H	H	M, /	95.00	B
H K H L C., L.	LLC	H	H	M, /	98.00	I
H K H L C., L.	LLC	H	H	M, /	100.00	I
H K H L C., L.	LLC	H	H	M, /	100.00	I
H K H L C., L.	LLC	H	H	M, /	80.00	I
H K H L C., L.	LLC	H	H	M, /	64.55	B
H K H L C., L.	LLC	H	H	M, /	100.00	I
H K H L C., L.	LLC	H	H	M, /	100.00	I
H K H L C., L.	LLC	H	H	M, /	100.00	I
H K H L C., L.	LLC	H	H	M, /	66.00	B
H K H L C., L.	LLC	H	H	M, /	100.00	I
H K H L C., L.	LLC	H	H	M, /	100.00	I
H K H L C., L.	LLC	H	H	M, /	100.00	I
H K H L C., L.	LLC	H	H	M, /	100.00	I

Next the Florida State e

F_ n _ n , , 30 J 2023

(A - RMB_A - n ,)

$$|1\rangle = \frac{1}{\sqrt{2}} \begin{pmatrix} 1 \\ -1 \end{pmatrix}$$

(I) Inter-subdomain (continued)

1. $\frac{1}{n} G_{-} (-, \cdot)$

Shah, d. g (%)

Nome da Subida	Tipo de Empresa	Capital	Pace f, eg, al	Nome da Subida	d, ex	i, d, ex	Método de Avaliação
L n K H C., L,	LLC	n	n	M, /	80.00		I _ _ _
O n ^ E, H C., L,	LLC	n	n	M, /	100.00		I _ _ _
Q ^ K H C., L,	LLC	L n	L n	M, /	100.00		I _ _ _
W n ^ M, I / C., L,	LLC	W n	W n	M, /	100.00		I _ _ _
n C H C., L,	LLC	n	n	M, /	100.00		B _ _ _ _ _
							' _ _ _ _ _
n K J, F, C	LLC	n	n	-	100.00		I _ _ _
n L n ^ H C., L,	LLC	n	n	M, /	60.00		I _ _ _
^ K H C., L,	LLC	n	n	M, /	100.00		I _ _ _
P C n ^ H C., L,	LLC	n	n	M, /	100.00		B _ _ _ _ _
							' _ _ _ _ _
J W H C., L,	LLC	L n	L n	M, /	51%		B _ _ _ _ _
							' _ _ _ _ _
^ ^ I , C n ,	LLC	n	n	M, /	100%		B _ _ _ _ _
M, H C., L,							' _ _ _ _ _
(樂清怡寧中西醫結合醫院有限公司)							
n A ^ P n C., L,	LLC	n	n	P n		100%	B _ _ _ _ _
							' _ _ _ _ _
L , K K H L ,	LLC	n	n	M, /	51%		B _ _ _ _ _
L C							' _ _ _ _ _
n ^ H n n _ _ C., L,	LLC	n	n	H n _		55%	I _ _ _
(溫州育己健康科技有限公司)							

(A - RMB) - n

(I) Inter-subdomain (continued)

Na e f Subda,	Shah d. g Percentage f -c r, l. g Shah de,	Cu, e r, f -c r, l. g Shah de,	Cu, e r d i d e -c r, l. g Shah de,	C- g baa ce f -c r, l. g Shah de,
2 L n ^ H_ C_, L,	40.00	-152,322.75		25,815,007.53
B ^ H_ C_, L,	49.00	-1,303,295.32		493,375.06
^ n ^ H_ C_, L,	45.00	-1,135,105.18		-4,216,850.65

Ba a ce a t h e e d f h e e d

Na e f Subda,	Cu, e t a b r e	N . -cu, e t a b r e	T r a a b r e	Cu, e t a b r e	N . -cu, e t a b r e	T r a a b r e
n L n ^ H_ C_., L,	16,018,641.11	109,972,839.43	125,991,480.54	16,453,961.72	45,000,000.00	61,453,961.72
B ^ H_ C_., L,	9,087,981.68	5,505,555.13	14,593,536.81	12,857,315.61	729,333.33	13,586,648.94
n ^ H_ C_., L,	15,080,218.50	13,653,288.40	28,733,506.90	37,586,947.22	517,338.90	38,104,286.12

N		C	N	C	N
1	1	19,028,799.19	98,436,498.17	20,546,971.67	45,000,000.00
2	2	10,169,929.61	8,893,422.97	14,393,845.02	1,002,833.33
3	3	14,488,059.45	19,086,594.25	34,702,253.46	5,720,723.50

Next the Florida State e

F_ n _ n , , 30 J 2023

(A - RMB_A - n ,)

$$\{1, 1, 1, \dots, n\} \quad (n \geq 1)$$

(I) Let e be a subarray (c is used)

3. $M = \begin{pmatrix} 1 & 0 & 0 \\ 0 & 1 & 0 \\ 0 & 0 & 1 \end{pmatrix}$

A part of the curriculum is

Na e f Subda,		Re e ue	Net, f	Tr a c t, che e f, l. c e	Ca n f e e f, e, al. g ad t e
B	u L n ^ H_ C_., L,		-380,806.87	-380,806.87	-3,609,574.58
B	u H_ C_., L,	7,978,933.21	-2,659,786.36	-2,659,786.36	-109,729.11
B	u H_ C_., L,	11,433,757.27	-2,522,455.96	-2,522,455.96	6,865,585.01

A _ _ n / _ _ /

C n

— $\hat{n}$ / — —

N	R	N	
B	259,074.72	259,074.72	1,060,125.05
B	7,938,336.05	-3,239,633.87	1,284,287.97
B	11,327,151.95	-3,051,974.81	262,948.82

(II) Interpretation, analysis and

1.  -

Shale, %

According to Wheeler, a degree of... the C... a...

1. Structure, De l'idée
2. à la réalisation, à la réalisation

[illegible]

(A - RMB, - n,)

2. M — — — — —

[illegible]

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

II. Accounting policies

1. Basis of preparation
The financial statements are prepared on the basis of the historical cost principle, except for the investment property measured at fair value.

2. Accounting period
The accounting period is from January 1 to December 31 of each year.

3. Fiscal year
The fiscal year is from January 1 to December 31 of each year.

4. Functional currency
The functional currency is the Renminbi (RMB).

5. Recognition and measurement of assets and liabilities
(I) Cash and cash equivalents
Cash and cash equivalents are recognized as assets when the company has a right to receive cash and the amount is reliable. Cash and cash equivalents are measured at fair value.

(I) Cash and cash equivalents

Cash and cash equivalents are recognized as assets when the company has a right to receive cash and the amount is reliable. Cash and cash equivalents are measured at fair value.

(II) Accounts receivable
Accounts receivable are recognized as assets when the company has a right to receive cash and the amount is reliable. Accounts receivable are measured at fair value.

(III) Inventory
Inventory is recognized as an asset when the company has a right to receive cash and the amount is reliable. Inventory is measured at fair value.

(IV) Property, plant and equipment
Property, plant and equipment are recognized as assets when the company has a right to receive cash and the amount is reliable. Property, plant and equipment are measured at fair value.

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(Amount in RMB, unless otherwise specified)

II. Revenue (Continued)

(I) Contract revenue (continued)

Contract revenue is recognized when the company has satisfied the following conditions: (1) the company has transferred control of the goods or services to the customer; (2) the company has no further significant obligations to the customer; (3) the company has received or has the right to receive the consideration; (4) the amount of revenue can be reliably measured; (5) it is probable that the company will receive the consideration; (6) the costs incurred or to be incurred in connection with the contract can be reliably measured. For contracts with a significant financing component, the company recognizes revenue at the fair value of the consideration received or receivable, adjusted for the time value of money. For contracts with a significant financing component, the company recognizes revenue at the fair value of the consideration received or receivable, adjusted for the time value of money. For contracts with a significant financing component, the company recognizes revenue at the fair value of the consideration received or receivable, adjusted for the time value of money.

(II) License revenue

License revenue is recognized when the company has satisfied the following conditions: (1) the company has transferred control of the license to the customer; (2) the company has no further significant obligations to the customer; (3) the company has received or has the right to receive the consideration; (4) the amount of revenue can be reliably measured; (5) it is probable that the company will receive the consideration; (6) the costs incurred or to be incurred in connection with the contract can be reliably measured. For contracts with a significant financing component, the company recognizes revenue at the fair value of the consideration received or receivable, adjusted for the time value of money. For contracts with a significant financing component, the company recognizes revenue at the fair value of the consideration received or receivable, adjusted for the time value of money. For contracts with a significant financing component, the company recognizes revenue at the fair value of the consideration received or receivable, adjusted for the time value of money.

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All figures in RMB, unless otherwise specified)

II. Revenue (continued)

(II) Revenue (continued)

The following table shows the breakdown of revenue by category and period:

Revenue	Contract type					Total
	Contract type	With 1 year	1-2 years	2-5 years	Over 5 years	
Revenue		174,060.00				174,060.00
Revenue		300,170,000.00	223,354,176.00	165,090,144.00	69,285,680.00	757,900,000.00
Revenue		24,992,499.08				24,992,499.08
Revenue		29,580,000.00	4,689,517.60	26,076,534.51		60,346,052.11
-		354,916,559.08	228,043,693.60	191,166,678.51	69,285,680.00	843,412,611.19

Revenue	Revenue by contract type					Total
	Contract type	1 year	1-2 years	2-5 years	Over 5 years	
Revenue		997,944.00				997,944.00
Revenue		211,396,818.18	223,154,176.00	153,052,040.00	69,285,680.00	656,888,714.18
Revenue		99,580,000.00	28,954,752.75	26,076,534.51		154,611,287.26
-		311,974,762.18	252,108,928.75	179,128,574.51	69,285,680.00	812,497,945.44

(III) Management

Management fees are charged to the company by the management team for their services. The fees are calculated based on the company's revenue and are payable in cash.

1. Management fees are charged to the company by the management team for their services. The fees are calculated based on the company's revenue and are payable in cash.

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(Amount in RMB, unless otherwise specified)

II. Revenue (in million RMB)

(III) Main business revenue (continued)

2. Revenue from contracts with customers

Revenue from contracts with customers is recognized when the company has satisfied the following conditions:

The company has transferred the control of the goods or services to the customer, and the customer has accepted the goods or services. The company has received the payment or the payment is due. The company has transferred the ownership of the goods or services to the customer, and the customer has accepted the goods or services. The company has received the payment or the payment is due. The company has transferred the ownership of the goods or services to the customer, and the customer has accepted the goods or services. The company has received the payment or the payment is due.

The company has transferred the ownership of the goods or services to the customer, and the customer has accepted the goods or services. The company has received the payment or the payment is due. The company has transferred the ownership of the goods or services to the customer, and the customer has accepted the goods or services. The company has received the payment or the payment is due.

Item	Contractual basis			Balance		
	US\$	HK\$	Total	US\$	HK\$	Total
Contract revenue	591,799.81	49,933.71	641,733.52	880,734.82	50,073.95	930,808.77
-	591,799.81	49,933.71	641,733.52	880,734.82	50,073.95	930,808.77

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All figures in RMB, unless otherwise specified)

III. Description of the Company's Business

The Company is a company limited by shares, established in accordance with the provisions of the Company Law of the People's Republic of China. The Company is engaged in the business of providing medical services. The Company's business scope is as follows:

1. The Company is engaged in the business of providing medical services. The Company's business scope is as follows:

2. The Company is engaged in the business of providing medical services. The Company's business scope is as follows:

3. The Company is engaged in the business of providing medical services. The Company's business scope is as follows:

(I) Classification of the Company's Business

Item	Classification of the Company's Business			Total
	Measured at fair value	Measured at fair value	Measured at fair value	
	Level 1	Level 2	Level 3	
I. Classification of the Company's Business				
Fair value				
1. Fair value			10,641,026.00	10,641,026.00
(1) Fair value				
(2) Fair value			10,641,026.00	10,641,026.00
(3) Fair value				
2. Fair value				
Total fair value			10,641,026.00	10,641,026.00
Fair value			13,922,929.38	13,922,929.38
1. Fair value			13,922,929.38	13,922,929.38
(1) Fair value				
(2) Fair value				
(3) Fair value			13,922,929.38	13,922,929.38
2. Fair value				
Total fair value			13,922,929.38	13,922,929.38

Notes to the Financial Statements

For the period ending June 30, 2023

(Amount in RMB, unless otherwise specified)

III. D. ()

(II) Quantitative and qualitative information about the financial statements and the related information, including the following information, are provided in the financial statements.

1. M
2. M

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Basic assumptions

- (I) General principle of the accounting
- On the basis of the Company's actual business transactions and other economic activities, the Company has adopted the following accounting principles:
- (II) If the Company's business transactions are not completed, the Company will follow the following principles:
- (III) If the Company's business transactions are not completed, the Company will follow the following principles:
- For the period from January 1, 2023 to June 30, 2023, the Company has adopted the following accounting principles:
- On the basis of the Company's actual business transactions and other economic activities, the Company has adopted the following accounting principles:

Name of the business transaction	Relevant accounting principle
Holding of shares, etc.	Accounting for equity
Contractual obligations, etc.	Accounting for liabilities
Contractual obligations, etc.	Accounting for liabilities
Holding of shares, etc.	Accounting for equity

F_ n _ n , , 30 J 2023

$$I \in R \quad , \quad \quad , \quad \quad , \quad \quad - \quad (- \quad ,)$$

Name of the, eaded type: _____ Other, eaded type: _____, ead - _____ in the C r a

G $\rightarrow$ n $\rightarrow$ L D $\rightarrow$ $\rightarrow$ $\rightarrow$

H₁ D $\rightarrow$ H₂ C₁, L₁ I /

N $\rightarrow$ M n B₁, P₁ A K n P n n₁ C₁ ' $\rightarrow$

I / M P n

(L₁, L₂ P n)

(寧波梅山保稅港區寬展
投資管理合夥企業(有限合夥))

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(Amount in RMB, unless otherwise specified)

1. Basic Information (Continued)

(V) Intangible Assets

1. Intangible Assets

Intangible Assets	Original Value	Accumulated Amortization	Net Book Value
Patent	1,485,148.50	1,500,000.00	
Software	55,550.20		

2. Intangible Assets

Intangible Assets

Intangible Assets	Original Value	Accumulated Amortization	Net Book Value
Patent	85,333.36	73,142.88	

Notes to the Financial Statements

Financial statements for the period ending June 30, 2023
(Amounts in RMB, unless otherwise specified)

1. Basis of Preparation (Continued)

(V) Leases (Continued)

3. Right-of-use assets

Right-of-use assets are measured at:

Name of lease asset				Guaranteed residual value	Lease term	Expiration date	Whether the lease asset has been fully depreciated
^	K	H	C., L.	50,200,000.00	2019/8/26	2029/8/20	N
Q	K	H	C., L.	45,000,000.00	2019/12/31	2024/12/31	N

Right-of-use assets are measured at:

Name of lease asset				Guaranteed residual value	Lease term	Expiration date	Whether the lease asset has been fully depreciated
G	,	L		27,000,000.00	2020/6/30	2027/6/30	N
G	,	H	, L	90,000,000.00	2021/11/29	2028/11/29	N
G	,	H	, L , ^	218,000,000.00	2020/10/26	2026/10/25	N
G	,	L	, H	220,000,000.00	2020/9/17	2023/9/17	N
G	,	L		24,500,000.00	2022/6/1	2025/6/1	N

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Basic Information

(V) Information about the Company's subsidiaries (continued)

4. Subsidiaries		Accounting method	Shareholding ratio
Subsidiary Name	Business scope	Accounting method	Shareholding ratio
Ningbo Meishan Bonded Zone Wanjian Investment Management Co., Ltd. (寧波梅山保稅港區寬展投資管理合夥企業(有限合夥))	Investment management	Cost of equity	33.7591%
Qinghai Kunming	5% shareholding	Cost of equity	500,000.00
5. Other subsidiaries		Accounting method	Shareholding ratio
R		Cost of equity	3,215,037.52

2,965,119.82

Notes to the Financial Statements

Financial statements for the period ending 30 June 2023

(Amounts in RMB, unless otherwise specified)

1. Basis of preparation (continued)

(VI) Receivables, allowances, and provisions

1. Receivables

Basis of preparation	Balance at the end of the period
	Amount / -

Provision for

Receivables

Receivables

Balance

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

(). ()

(I) Significant accounting policies and estimates (continued)

On August 16, 2021, the company issued a total of 100 million shares of ordinary shares at a price of RMB10.47 per share, raising a total of RMB1,047 million. The net proceeds of RMB1,047 million were used for the purchase of land and construction of the new hospital building. As of August 16, 2021, the company had received a total of RMB540,229 million from the issuance of shares, and the balance of the share premium account was RMB13 million.

The company's accounting policy for the share premium account is as follows:

The company's accounting policy for the share premium account is as follows:

When the company issues shares, the share premium account is recorded as follows:

The company's accounting policy for the share premium account is as follows:

(II) Estimated significant accounting policies and estimates

The company's accounting policy for the share premium account is as follows:

The company's accounting policy for the share premium account is as follows:

The company's accounting policy for the share premium account is as follows:

In July 2021, the company issued a total of 100 million shares of ordinary shares at a price of RMB10.47 per share, raising a total of RMB1,047 million. The net proceeds of RMB1,047 million were used for the purchase of land and construction of the new hospital building. As of July 2021, the company had received a total of RMB540,229 million from the issuance of shares, and the balance of the share premium account was RMB13 million.

The company's accounting policy for the share premium account is as follows:

The company's accounting policy for the share premium account is as follows:

As of June 30, 2023, the company's share premium account balance was RMB44,857,374.20.

The company's accounting policy for the share premium account is as follows:

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

(). ()

(III) Modification and cancellation of long-term equity investments

In June 2021, the Company held a shareholders' meeting to discuss the modification and cancellation of long-term equity investments. The Company decided to modify the long-term equity investments in the amount of RMB 100,000,000.00, and the modification was completed in July 2021. The Company decided to cancel the long-term equity investments in the amount of RMB 100,000,000.00, and the cancellation was completed in July 2021.

I. Cancellation of long-term equity investments

1. Cancellation of long-term equity investments

As of June 30, 2023, the Company has cancelled long-term equity investments in the amount of RMB 100,000,000.00.

(I) Cancellation of long-term equity investments

The Company has cancelled long-term equity investments in the amount of RMB 100,000,000.00.

II. Elimination of long-term equity investments

(I) Elimination of long-term equity investments

Nil.

(A - RMB₁ - n,)

D	/	-	49.62%	49.73%
---	---	---	--------	--------

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023

(Amount in RMB, unless otherwise specified)

1. Basis of Preparation

(I) Accounting Policies

1. Accounting Policies

Accounting	Balance Sheet	Income Statement
Assets	41,292,202.90	49,024,983.98
Liabilities	257,315.13	709,878.26
Equity	709,878.26	1,158,221.95
Other	3,906,521.87	2,748,299.92
Total	46,165,918.16	53,641,384.11
Losses	5,286,637.29	5,361,391.95
Total	40,879,280.87	48,279,992.16

2. Accounting Policies

Category	Balance Sheet				Income Statement			
	Assets		Liabilities		Expenses		Income	
	Amount	Percentage (%)	Amount	Percentage (%)	Amount	Percentage (%)	Amount	Percentage (%)
Prepaid Expenses	4,873,715.26	10.56	4,873,715.26	100.00	4,873,715.26	9.09	4,873,715.26	100.00
Medical Expenses	4,873,715.26	10.56	4,873,715.26	100.00	4,873,715.26	9.09	4,873,715.26	100.00
Prepaid Expenses	41,292,202.90	89.44	412,922.03	1.00	40,879,280.87	48,767,668.85	90.91	48,767,668.85
Other	41,292,202.90	89.44	412,922.03	1.00	40,879,280.87	48,767,668.85	90.91	48,767,668.85
Total	46,165,918.16	100.00	5,286,637.29	1.00	40,879,280.87	53,641,384.11	100.00	53,641,384.11

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements

(I) Accounts receivable (continued)

2. Accounts receivable (continued)

Item	Balance at the end of the period			
	Balance	Provision for bad debts	Provision for bad debts, %	Realized provision
Medical services	4,873,715.26	4,873,715.26	100	-
-	4,873,715.26	4,873,715.26	/	-

Provision for bad debts:

Item	Balance at the end of the period		
	Accounts receivable	Provision for bad debts	Provision for bad debts, %
Other	41,292,202.90	412,922.03	1.00
-	41,292,202.90	412,922.03	/

3. Prepaid expenses

Category	Change in the current period			
	Balance at the beginning of the period	Added	Reduced	Balance at the end of the period
Prepaid medical insurance	-	-	-	-

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(Amount in RMB, unless otherwise specified)

1. Notes to the Financial Statements

(II) Other receivables

	Balance at the end of the reporting period	Balance at the beginning of the reporting period
1. Dividends receivable		
Dividends receivable from subsidiaries	53,000,000.00	53,000,000.00
Others	474,620,871.01	547,014,558.58
	527,620,871.01	600,014,558.58

1. Dividends receivable

	Balance at the end of the reporting period	Balance at the beginning of the reporting period
1. Dividends receivable		
Cash dividends receivable from subsidiaries	33,000,000.00	33,000,000.00
Dividends receivable from subsidiaries	10,000,000.00	10,000,000.00
Dividends receivable from subsidiaries	10,000,000.00	10,000,000.00
	53,000,000.00	53,000,000.00
Less: Provision for impairment of dividends receivable		
	53,000,000.00	53,000,000.00

2. Others receivable

(1) Debtors

	Balance at the end of the reporting period	Balance at the beginning of the reporting period
Ageing		
Within 1 year	472,453,825.45	249,636,171.19
1-2 years	981,558.90	237,554,656.40
2-3 years	513,575.80	29,146,078.54
Over 3 years	859,143.18	30,904,134.11
	474,808,103.33	547,241,040.24
Less: Provision for impairment of debtors	187,232.32	226,481.66
	474,620,871.01	547,014,558.58

Notes to the Financial Statement

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statement

(II) Other receivables (continued)

2. Other receivables (continued)

(2) Details of other receivables

Category	Basis of measurement					Basis of measurement				
	Basis of measurement		Basis of measurement		Basis of measurement	Basis of measurement		Basis of measurement		
	Amount	Proportion (%)	Amount	Proportion (%)		Amount	Proportion (%)	Amount	Proportion (%)	
Prepaid expenses	474,808,103.33	100.00	187,232.32	0.04	477,641,010.84	547,241,040.24	100.00	226,481.66	0.04	547,014,558.58
Accounts receivable	70,875,967.57	14.93	187,232.32	0.26	70,688,735.25	8,071,564.48	1.47	226,481.66	2.81	7,845,082.82
Accounts payable	403,932,135.76	85.07			406,952,275.59	539,169,475.76	98.53			539,169,475.76
Total	474,808,103.33	100.00	187,232.32		477,641,010.84	547,241,040.24	100.00	226,481.66		547,014,558.58

Prepaid expenses are measured at cost less impairment.

Item	Basis of measurement		
	Other receivables	Prepaid expenses	Proportion (%)
Accounts receivable	70,875,967.57	187,232.32	0.26
Accounts payable	406,952,275.59		
Total	477,828,243.16	187,232.32	/

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. The Company's financial statements are prepared in accordance with the accounting standards and accounting policies of the People's Republic of China.

(II) Other disclosures (continued)

2. On June 30, 2023, the Company's financial position is as follows:

(3) The Company's financial position is as follows:

	Stage 1	Stage 2	Stage 3	
		Life expectancy ECL (N ceteris paribus)	Life expectancy ECL (N ceteris paribus)	
Provision for bad debts	12-month ECL	12-month ECL	12-month ECL	Total

(A - RMB₁ - n,)

$$C_n = \frac{n!}{2^n} \left(1 - \frac{1}{n} \right)^{n-1} \left(1 + \frac{1}{n} \right)^{n-1} \left(1 - \frac{1}{n} \right)^{n-1} \left(1 + \frac{1}{n} \right)^{n-1} \dots$$

	<u>Sage 1</u>	<u>Sage 2</u>	<u>Sage 3</u>
B base	12- month ECL	Life e ECL (Net credit portfolio)	Life e ECL (Credit portfolio)
B n / - n			
/ -	547,241,040.24		547,241,040.24
B n / - n / -			
n , / / /			
n -			
- - 2			
- / - 3			
- R / / / - 2			
- R / / / - 1			
A / - - - n -			
D - - - n -	69,412,797.08		69,412,797.08
O n n			
B n / - n -	477,828,243.16		477,828,243.16

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. The Company has no significant changes in the scope of consolidated financial statements during the reporting period.

(II) Other accounting policies (continued)

2. On June 30, 2023, the Company's financial statements are as follows:

(4) Payable for purchase of goods, services, and other receivables

Category	Amount of change during the reporting period			
	Balance at the beginning of the reporting period	Added during the reporting period	Reduced during the reporting period	Balance at the end of the reporting period
Payable for purchase of goods, services, and other receivables	226,481.66	39,249.34	-	187,232.32
-	226,481.66	39,249.34	-	187,232.32

(5) Other receivables

Name	Balance at the beginning of the reporting period	Balance at the end of the reporting period
Accounts receivable	403,932,135.76	507,207,052.64
Receivable from related parties	46,632,118.55	33,132,118.55
Due from government	5,933,150.00	5,933,350.00
Other receivables	15,130,000.00	-
Other receivables	3,180,699.02	968,519.05
-	474,808,103.33	547,241,040.24

F_ n _ n , , 30 J 2023

(A - RMB, - n,)

$$I_N = \frac{1}{N} \sum_{i=1}^N \left(\frac{1}{\sigma_i^2} \right) = \frac{1}{N} \sum_{i=1}^N \left(\frac{1}{\sigma_i^2} \right) = \frac{1}{N} \sum_{i=1}^N \left(\frac{1}{\sigma_i^2} \right)$$

(III) L. g^{re} e. u^r i. ~~e~~ ~~e~~

Taxes	Baa ced the ed the ed		B n / n /	
	B baa ce	P, a, e	B aue	B a /
1 /	670,246,492.72	670,246,492.72	649,079,592.72	649,079,592.72
1 /	92,385,700.59	92,385,700.59	92,882,992.81	92,882,992.81
-	762,632,193.31	762,632,193.31	741,962,585.53	741,962,585.53

1. / /

	B	P, a, f, l a, e
L, a, e	n, l, e	l, a, e
	l, a, e	l, a, e
M, l, C, L,	10,354,979.06	10,000,000.00
K, K, H, C, L,	15,500,000.00	15,500,000.00
J, F, l	500,000.00	500,000.00
H, M		
C, L,	204,666,253.87	204,666,253.87
K, H, C, L,	52,697,737.50	52,697,737.50
K, H, C, L,	2,133,258.38	2,133,258.38
K, H, C, L,	27,687,093.11	27,687,093.11
K, H, C, L,	32,856,644.25	32,856,644.25
K, H, C, L,	2,299,071.39	2,500,000.00
C, H, C, L,	53,500,000.00	53,500,000.00
L, n, H, C, L,	30,000,000.00	10,800,000.00
O, n, R, n, -		
H, C, L,	10,000,000.00	10,000,000.00
C, n, H, C, L,	154,744,700.00	154,744,700.00
H, C, L,	26,684,900.00	2,366,900.00
I, C, n, ,		
M, H, C, L,	40,954,955.16	40,954,955.16
-	649,079,592.72	31,166,900.00
		10,000,000.00
		670,246,492.72

Next the Florida State e

F_ n _ n , , 30 J 2023

(A - RMB_A - n ,)

[illegible]

Notes to the Financial Statements

For the period from January 1, 2023 to June 30, 2023
(All amounts in RMB, unless otherwise specified)

1. Notes to the Financial Statements

(IV) Revenue and Expenses

1. Revenue and Expenses

Item	Amount		Amount	
	Revenue	Cost	Revenue	Cost
Medical	174,575,542.75	130,786,397.79	183,506,368.69	133,177,435.95
Others	1,629,256.25	-	2,293,730.40	45,300.00
-	176,204,799.00	130,786,397.79	185,800,099.09	133,222,735.95

Amount in thousands of RMB

Item	Amount		Amount	
	Revenue	Cost	Revenue	Cost
Pharmaceuticals	43,231,464.13	-	44,016,314.26	-
-	131,344,078.62	-	139,490,054.43	-
-	174,575,542.75	-	183,506,368.69	-

2. Expenses

Expenses are incurred in the course of the company's business activities, including but not limited to salaries, social security, housing fund, medical insurance, etc.

(V) Income and Expenses

Item	Amount		Amount	
	Revenue	Cost	Revenue	Cost
Interest income	-	-	594,000.00	-
Interest expense	-	-	816,165.55	-1,296,180.45
Interest income	-	-	-1,591,713.27	-
Interest expense	-	-	-	-
-	-	-	-775,547.72	-702,180.45

Def. 定义

A. 公司 C. 公司 B. 公司

B. 公司 H. 公司 C. 公司, L. 公司 (北京怡寧醫院有限公司),
n PRC n 公司, 公司 A 17, 2015, 公司 C. 公司, 公司

B. 公司 D. 公司 B. 公司 n 公司, 公司 C.

C. 公司 K. 公司 H. 公司 C. 公司, L. 公司 (蒼南康寧醫院有限公司),
n PRC n 公司, 公司 J 15, 2012, 公司 C. 公司, 公司

C. 公司 L. 公司 n C. 公司 L. 公司 P. 公司 R. 公司 Cn

CG C. 公司 n C. 公司 G. 公司 C. 公司, 公司 A 14 公司 H. 公司 K. 公司 L. 公司 R

Cn 公司 K. 公司 P. 公司 H. 公司 C. 公司, L. 公司 (長春康林心理醫院有限公司),
公司 n PRC n 公司, 公司 F. 公司 16, 2016, 公司 C. 公司, 公司

C. 公司 K. 公司 H. 公司 C. 公司, L. 公司, 公司
K. 公司 H. 公司 n 公司, 公司 n PRC, n H. 公司 n M
B. 公司 n H. 公司 K. 公司 E. 公司 (C. 公司 : 2120)

D. 公司 () n 公司 () n C.

D. 公司 () n 公司 () n 公司 n C. 公司, 公司 / 公司 RMB1.00
n 公司 n 公司 RMB 公司, 公司 n
公司, 公司, 公司

G. 公司 H. 公司 n 公司 G. 公司 H. 公司 C. 公司, L. 公司 (溫州怡寧老年醫院有限公司),
公司 n PRC n 公司, 公司 N. 公司 2, 2015, 公司 C. 公司, 公司
公司, 公司, 公司 n 公司, 公司, 公司

G. 公司 n C. 公司, 公司

G	H	G	H
C., L. (冠縣怡寧醫院有限公司), PRC , M 01, 2017, C-			
H	()	- / , / , n () n - n C- , n - RMB1.00 n M B- n H- K- E n	
H	n C H	H n C H C., L. (杭州慈寧醫院有限公司), n PRC n N- / 18, 2017, C-	
H	n H	H n P n H C., L. (荷澤怡寧精神病醫院有限公司), n PRC n A 6, 2017, C-	
HKD		n H- K-	
H- K-		n H- K- A / R - n PRC	
H- K- L R		n R G- / n L - E n H- K- L , , - n -	
H- K- E n		n E n H- K- L ,	
I	/ ()	N- , D- E I / P n n - , n n, A - n - , n E I / I / P n n - , n n, n I / n , n / - / - / - n , n - / - , n C- , n n - n I / -	
J	H	J H C., L. (緡雲舒寧醫院有限公司), n PRC n F 15, 2019, C-	
L , K H		L , C K K H C., L. (婁底市康樂康寧醫院有限責任公司), n PRC n A 28, 2017, C-	

Def. 11

L n H- C., L. (温州鹿城怡寧醫院有限公司),
n PRC n A 2, 2020, n C-

M n M A / R n PRC

M, C, n M, C, D L I
A 10 n H- K- L R

N- C- n B-

P () D , / - n G- (, n
, - n () - , / - n , n
- - n B- , n , n n / - n E
I / n n I /

P Cn P Cn H- C., L. (平陽長庚怡寧醫院有限公司),
n PRC n J 14, 2021, n
C- n -

P H H- C., L. (浦江怡寧黃鋒醫院有限公司),
n PRC n 3, 2018, n
C- n -

PRC - Cn n P- ' R - Cn n n - n - ,
H- K- , M A / R n PRC

P- , I D , ,

Def. ni

R _ P _	n _ n , J 30, 2023
R _ C_	n _ _ _ n B_
RMB	n _ n PRC
人民币	n 人民币, F O, (Cn 571 _ n L _ H_ K_),
人民币 ()	n () n n _ n C_ , n _ / _ RMB1.00 n , n D_ 人民币 () , n H_人民币 ()
人民币 ()	n () _ n 人民币 ()
人民币 n ^ H_	人民币 n ^ H_ (深圳怡寧醫院, / _ _ _ 人民币 n ^ H_ C_ , L_ (深圳市怡寧醫院有限公司)), _ n , n PRC n , _ _ 22, 2014, _ _ n C_ , _ _ n
人民币 , R ^ M C_	n , ^ _ _ _ n B_
人民币 _ _	n n _ , n _ n C_ O, (Cn 622 _ n L _ H_ K_)
人民币 n ()	n n _ , n _ n H_ K_ L R
人民币 / _ ()	n _ _ n 人民币 / _ C_
人民币 / _ C_	n C_ , / _ _ n , _ n PRC C_ L
人民币 n O n ^ E, H_	n O n ^ E, H_ C_ , L_ (温州瓯海怡寧老年醫院有限公司), _ n , Cn n , _ _ M n8, 2021, _ _ n _ _ n C_
人民币 P n _ I H_	人民币 P n _ I H_ (_ n) C_ , L_ (怡寧心理互聯網醫院(温州)有限公司), _ n , n PRC n , _ _ M n10, 2020, _ _ n C_ , _ _ n

Def. 11

Wenzhou Kangning Hospital Co., Ltd.	Wenzhou Kangning Hospital Co., Ltd. (永嘉康寧醫院有限公司),
PRC	D 12, 2012, C
Wenzhou Kangning Hospital Co., Ltd.	Wenzhou Kangning Hospital Co., Ltd. (樂清康寧醫院有限公司),
PRC	3, 2013, C
%	-

温州康宁医院 股份有限公司
Wenzhou Kangning Hospital Co., Ltd.